
Title: A Phase 1b, 4-Period Crossover, Placebo-Controlled, Randomized, Single Dose Study to 
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in 
Sleep-Deprived Healthy Adults Utilizing Modafinil as an Active Comparator
Study ID: [REMOVED]
Protocol Approve Date: 08 May 2018
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1b, 4 -Period Crossover, Placebo- Controlled, Randomized, Single Dose Study to 
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK -925 in 
Sleep -Deprived Healthy Adults Utilizing Modafinil as an Active Comparator
Study Identifier: TAK-925-1002
Compound: TAK-925
Date: 08May 2018
Version/Amendment 
Number:01
Date Amendment Number Region
08 March 2018 Initial Protocol United States
08May 2018 01 United States
Property of Taked mercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 2of 91
Protocol Incorporating Amendment No. 01 08 May 2018
TABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
1.1 Protocol  Amendment 01 Summary  of Changes ........................................................ 11
2.0 STUDY SCHEMATIC .................................................................................................. 12
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 13
4.0 INTRODUCTION ......................................................................................................... 17
4.1 Backgrou nd............................................................................................................. 17
4.2 Rationale for the Proposed Study ............................................................................. 18
4.3 Benefit/Risk Profile .................................................................................................19
4.3.1TAK -925 ........................................................................................................... 19
4.3.2 Modafinil ........................................................................................................... 21
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 23
5.1 Object ives................................................................................................................ 23
5.1.1 Primary Object ive.............................................................................................. 23
5.1.2 Secondary  Object ives......................................................................................... 23
5.1.3 Exploratory  Objectives ....................................................................................... 23
5.2 Endpoints ................................................................................................................. 24
5.2.1 Primary Endpo int............................................................................................... 24
5.2.2 Secondary  Endpo ints.......................................................................................... 24
5.2.3 Safety Endpo ints................................................................................................ 25
5.2.4 Exploratory  Endpo ints....................................................................................... 25
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 26
6.1 Study  Design ........................................................................................................... 26
6.2 Rationale for Study  Design, Dose, and Endpoints .................................................... 27
6.2.1 Rationale of Study  Design .................................................................................. 27
6.2.2 Rationale for Dose ............................................................................................. 28
6.2.3Rationale for Endpoints ...................................................................................... 29
6.2.4 Critical Procedures Based on Study  Object ives: Timing of Procedures ............... 31
6.3 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 31
6.4 Study  Beginning and End/Co mpletion..................................................................... 32
6.4.1 Definit ion of Begi nning o f the Study .................................................................. 32
6.4.2 Definit ion of End of the Study ........................................................................... 32
6.4.3 Definit ion of Study  Discont inuat ion................................................................... 32
6.4.4 Criteria for Premature Terminat ion or Suspension of the Study .......................... 33
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 3of 91
Protocol Incorporating Amendment No. 01 08 May 2018
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 34
7.1 Inclusio n Cri teria..................................................................................................... 34
7.2 Exclusio n Cri teria.................................................................................................... 35
7.3 Excluded Medicat ions, Supplements, Dietary  Products ............................................ 36
7.3.1 Concomitant Medications ................................................................................... 36
7.3.2 Fruit Juice.......................................................................................................... 36
7.3.3 Alcoho l.............................................................................................................. 36
7.3.4 Caffeine ............................................................................................................. 37
7.3.5 Smoking ............................................................................................................ 37
7.4 Diet, Fl uids, and Act ivity......................................................................................... 37
7.4.1 Diet and Fluids ................................................................................................... 37
7.4.2 Activity.............................................................................................................. 37
7.5 Criteria f or Di scontinuati on or Wi thdrawal  of a Subject ........................................... 38
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 39
7.7 Subject Replacement ................................................................................................ 39
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 40
8.1 Clinical Study  Drug .................................................................................................40
8.1.1 Clinical Study  Drug Labeling ............................................................................. 40
8.1.2 Clinical Study  Drug Inventory  and Storage ........................................................ 40
8.1.3 Clinical Study  Drug Blinding ............................................................................. 40
8.1.4 Randomization Code Creation and Storage ........................................................ 40
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure .................................... 40
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................... 41
9.0 STUDY PROCEDURES ............................................................................................... 42
9.1 Administrative Procedures ....................................................................................... 42
9.1.1 Inform ed Consent Procedure .............................................................................. 42
9.1.2 Inclusio n and Exclusio n..................................................................................... 42
9.1.3 Medical History , Dem ographics, and Pri or and Conco mitant Medi cations......... 42
9.2 Clinical Procedures and Assessments ....................................................................... 43
9.2.1 Full Physical Examinat ion.................................................................................. 43
9.2.2 Height and Wei ght............................................................................................. 43
9.2.3 BMI ................................................................................................................... 43
9.2.4 Vital Signs ......................................................................................................... 43
9.2.5 Continuous Monitoring with Digital Techno logy............................................... 43
9.2.6 12-Lead ECG ................................ ..................................................................... 43
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 4of 91
Protocol Incorporating Amendment No. 01 08 May 2018
9.2.7 Study Drug Administration ................................................................................ 44
9.2.8 C-SSRS .............................................................................................................. 44
9.2.9 Drug -Liking VAS .............................................................................................. 45
9.2.10 Actigraphy ......................................................................................................... 45
9.2.11 Sleep Deprivati on............................................................................................... 45
9.2.12 AE Monitoring ................................................................................................... 45
9.2.13 Laboratory  Procedures and Assessments ............................................................ 45
9.3 PK, Bi omarker, PD, and Pharmacogeno mic Samples ............................................... 47
9.3.1 PK, Bi omarker, PD, and Pharmacogeno mic Evaluations .................................... 47
9.3.2 PK Measurements .............................................................................................. 47
9.3.3 Biomarker Measurem ents................................................................................... 48
9.3.4 PD Measurements .............................................................................................. 49
9.3.5 PGx Measurements ............................................................................................ 50
9.3.6 Confinement ...................................................................................................... 51
10.0 ADVERSE EVENTS .................................................................................................... 52
10.1 Definitions and El ements of AEs ............................................................................. 52
10.1.1 SAEs .................................................................................................................. 54
10.2 AE Procedur es......................................................................................................... 54
10.2.1 Assigning Severit y/Intensit y of AEs ................................................................... 54
10.2.2 Assigning Causalit y of AEs ................................................................................ 55
10.2.3 Start Date ........................................................................................................... 55
10.2.4 EndDate ............................................................................................................ 55
10.2.5 Pattern of AE (Frequency) ................................................................................. 55
10.2.6 Action Taken Wit h Study  Treatm ent.................................................................. 55
10.2.7 Outcom e............................................................................................................ 56
10.2.8 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and Abnormal 
LFTs .................................................................................................................. 56
10.2.9 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties.....58
11.0 STATISTICAL METHODS .......................................................................................... 59
11.1 Statistical and Analyt ical Plans ................................................................................ 59
11.1.1 Analysis Sets ...................................................................................................... 59
11.1.2 Analysis of Demography  and Other Baseline Characterist ics............................. 59
11.1.3 PK Analysis ....................................................................................................... 59
11.1.4 PD Analysis ....................................................................................................... 60
11.1.5 Safety Analysis .................................................................................................. 60
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 61
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 5of 91
Protocol Incorporating Amendment No. 01 08 May 2018
11.3 Determinat ion of Sample Size .................................................................................. 61
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 63
12.1 Study -Site Moni toring Visit s................................................................................... 63
12.2 Protocol  Deviat ions.................................................................................................. 63
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 63
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 64
13.1 IRB and/or IEC Approval ........................................................................................ 64
13.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 65
13.3 Subject Confidentialit y............................................................................................ 66
13.4 Publicat ion, Di sclosure, and Clinical Trial Registr ation Policy .................................66
13.4.1 Publicat ion and Disclosure ................................................................................. 66
13.4.2 Clinical Trial Registration .................................................................................. 67
13.4.3 Clinical Trial Result s Disclosure ........................................................................ 67
13.5 Insurance and Co mpensation for Injury .................................................................... 67
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 68
14.1 Administrative Informat ion...................................................................................... 68
14.1.1 Study  Contact Informat ion................................................................................. 68
14.1.2 INVESTIGATOR AGREEMENT ...................................................................... 69
14.1.3 Study -Related Responsibilit ies........................................................................... 70
14.1.4 List of Abbreviat ions......................................................................................... 70
15.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 72
15.1 CRFs (El ectronic and Paper) .................................................................................... 72
15.2 Record Retention ..................................................................................................... 72
16.0 REFERENCES .............................................................................................................. 74
17.0 APPENDICES ............................................................................................................... 77
LIST OF IN -TEXT TABLES
Table 4.a Summary  of Blinded TEAE Data From Study  TAK -925-1001 
(Cohorts 1and2, Healthy Adult Subjects a)....................................................... 21
Table 4.b Summary  of Blinded TEAE Data From Study  TAK -
925-1001 (Cohort 3, 
Healthy El derly  Adult Subjects a)................................
....................................... 21
Table 6.a Summary  of Study  Drug Assignment and Sequence (Double Dummy  for 
Placebo) ............................................................................................................. 26
Table 6.b Dosing and Sampling Scheme ............................................................................ 27
Table 9.a Primary Specimen Collections ........................................................................... 47
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 6of 91
Protocol Incorporating Amendment No. 01 08 May 2018
LIST OF IN -TEXT FIGURES
Figure 4.a Model  of Diurnal  Intrinsic OX Level in Brain Over Time .................................. 19
LIST OF APPENDICES
Appendix A Responsibilit ies o f the Invest igator ..................................................................... 77
Appendix B Elements of the Subject Informed Consent ......................................................... 79
Appendix C Invest igator Consent to the Use of Personal Information .................................... 82
Appendix D Pregnancy and Contraception ............................................................................. 83
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 86
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 7of 91
Protocol Incorporating Amendment No. 01 08 May 2018
1.0 STUDY SUMMARY
Name of Sponsor:
Takeda Pharmaceutical Company, Ltd
40 Landsdowne Street
Camb ridge MA 02139
USACompound:
TAK -925
Study Identifier: TAK -925-1002 Phase: 1b
Protocol Title: A Ph ase 1b, 4 -Period Crossover, Placebo -Controlled, Randomized, Single Dose Study to Evaluate the 
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK -925 in Sleep -Deprived Healthy Adults 
Utilizing Modafinil as an Active Comparator
Study Design:
Healthy  adult male subjects aged 18 to 40 years, inclusive, who satisfy inclusion and exclusion criteria will be enrolled 
in the study. On Day 1 of treatment period 1, eligible participants will be equally randomized to 4 treatment sequence 
groups (sequenc e 1 to 4) which define the order of the treatment administration (TAK -925 44mg [low dose , (LD)], 
TAK -925 112mg [high dose (HD)]mg [both delivered as a 9 -hour intravenous (IV) infusion], modafinil 300 mg, and 
placebo).
At the screening visit, subjects wi ll complete medical examinations, an electrocardiogram (ECG), and clinical 
laborato ry tests. After the screening visit, eligible participants will wear an actigraph from Day -6 until Day -1. After 
validation that actigraphy shows a normal sleep -wake cycle, and subjects have a negative drug screen, subjects will 
undergo an 8 -hour nocturnal polysomnography to exclude any sleep disorders. Actigraphy results will also be 
collected for the 5- night period before Day -1 (Day  -6 to Day  -1) for every treatment period to ensure that sleep falls 
within no rmal nocturnal times (defined under Inclusion Criteria).
During the day before dosing on Day 1, subjects will be administered the Ka rolinska Sleepiness Scale (KSS) and 
Camb ridge Cognitio nComputerized Battery of Tests (CCBT) at scheduled timepoints. A practice maintenance of 
wakefulness test (MWT) session, as well as a practice CCBT, will be performed on Day 1 of treatment period 1 (only 
once during the entire study) to familiarize subjects with the procedures. Study dru g will be administered in the clinic 
in the evening on Day 1 of each treatment period. Subjects will undergo the MWT, KSS, and CCBT at specified time 
points after the start of the infusion. Subjects will be required to stay awake in between the MWT tests. Following 
completion of the IV infusion on Day 2, subjects will undergo an additional MWT test. When the final MWT test and 
cognitive testing has been completed, subjects will be allowed to sleep (recover y sleep) for approximately 6 hours. 
Polysomnography (PSG) recording will be collected during this time. Subjects may be discharged from the unit after 
completion on Day 2 with continuing actigraphy upon discharge (to begin on Day -6 before the next treatment period). 
The interval of each subsequent treatment period will be at least 7 days to ensure that the subject’s circadian rhythm 
has returned to a normal cycle. Subject’s vital signs, including blood pressure (BP), will be continuously monitored 
during the dosing and testing periods. Blood samples for det ermination of TAK -925 plasma concentrations will be 
collected at specified timepoints on Days 1 and 2 of each treatment period. Subjects will complete the Columbia –
Suicide Severity Rating Scale (C -SSRS) during screening, before study drug administration, a nd before discharge on 
Day 2 of each treatment period. Subjects will complete the Profile of Mood States (POMS) before and post study drug 
administration, and undergo a drug-liking Visual Analog Scale (VAS) following recover y sleep in each treatment 
period .
Primary Objective:
To determine the effect of TAK -925 after a single IV infusion (compared to placebo) on promoting wakefulness as 
measured by sleep latency on the MWT (performed at approxim ately  2, 4, 6, and 8 hours post dosing starting at 
approximately 1:00 AM an d then at approximate times of 3:00, 5:00, and 7:00 AM) in sleep -deprived healthy 
volunteers.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 8of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Secondary Objectives:
1.To assess the safety/tolerability and pharmacokinetic (PK) parameters of a single IV infusion of TAK -925 in 
sleep -deprived healt hy volunteers.
2.To determine the effect of a single dose of modafinil (300 mg) on promoting wakefulness as measured by sleep 
latency on the MWT in order to confirm assay sensitivity.
3.To evaluate the effect of TAK -925, LD and HD, on a measure of sleepiness, as compared to placebo.
Study Subject Population: Healthy  male subjects, aged 18 to 40 years, inclusive.
Planned Number of Subjects:
Approximately 20 subjects randomizedPlanned Number of Sites:
1 site in the US
Dose Levels:
Study Drug
TAK -925 112 mg(HD)
TAK -925 44mg(LD)
Matching placebo
Modafinil
300 mg
Matching placeboRoute of Administration:
Study Drug
IV infusion
Modafinil
Oral (tablets)
Duration of Treatment:
1 dose of modafinil 300 mg or placebo followed by a 
continuous 9 -hour IV infusion of study drug (TAK -925 
HD mg, TAK -925 LD mg, or placebo) beginning in the 
evening on Day 1 of each of 4 treatment periodsPlanned Study Duration :
Up to approximately 12 weeks.
Main Criteria for Inclusion:
To be eligible for study participation, subjects m ust: 
1.Understand the study procedures and agree to participate by providing written informed consent.
2.Be willing and able to comply with all study procedures and restrictions.
3.Be a healthy  male ,aged 18 to 40 years, inclusive, at the screening v isit.
4.Have a body mass index ≥18.5 and ≤30.0 (kg/m2) at the screening v isit.
5.Be a nonsmoker or have not used tobacco -or nicotine -containing products (eg, nicotine patch) for at least 
6months before study drug administration of the initial dose of study drug.
6.Be jud ged to be in good health by the investigator, based on clinical evaluations including laboratory safety tests, 
medical history, physical examination, 12 -lead ECG, and vital sign measurements performed at the screening 
visit and before administration of the initial dose of study drug/invasive procedure.
7.Meet the specified birth control requirements .
8.Is a male subject who agrees to not donate sperm from trial drug administration on the first day of the first dose 
until 5 half -lives plus 90 days after the last dose of study drug administration.
9.Have r egular sleep -wake habits (eg, routinely spending 6.5 to 8 hours sleeping nightly, not oversleeping by m ore 
than 3 hours on weekends, ie , total sleep not more than 11 hours) as determined by investigator interviews and 
confirmed in 5 -day actigraphy records and w hom regularly  fall asleep between 9:30 PM and 12:00 AM .
10.Bewilling to have actigraphy monitoring during the week before randomization and in each interval.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 9of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Main Criteria for Exclusion:
The subject must be excluded from participating in the study if the subject: 
1.Has a positive alcohol or drug screen.
2.Has a histo ry of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately 
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or dist illed spirits [29.5 mL/1 ounce] per day).
3.Has excessive sleepiness defined by a self -reported Epworth Sleepiness Scale score at screening greater than 10; 
irregular work hours; or routine night -shift work within 1 month before randomization. 
4. Currently  experiencing o r having a history of any known/suspected sleep disorder, any disorder asso ciated with 
excessive daytime somnolence, or any diagnosis interfering with assessment of sleepiness.
5.Abnormal findings on the initial PSG conducted on Day -1 (check -in), as specified in the study manual.
6.Traveled across 2 or more time zones 2 weeks or les s before screening; 
7.Current o r previous history of serious, severe, or unstable physical or psychiatric illness that may affect sleep or 
wakefulness; any medical disorder that may make the full completion of the study unlikely.
8.Caffeine consumption of more than 400 mg/day for 2 weeks before screening (1 serving of coffee is 
approximately equivalent to 120 mg of caffeine).
9.Hypertension or history of hypertension. Systolic BP ≥140 mmHg o r diastolic BP ≥90 mmHg is excluded.
10.Other significant cardiovascular risk factors including abnormal ECG QT interval findings and heart rate ( HR).
11.Screening ECG reveals a QT interval with Frederica correct ion method >450 milliseconds.
Main Criteria for Evaluation and Analyses:
The primary endpoint of the study is:
1.Latency for each MWT, defined as time to sleep onset.
Sleep onset is defined as the first epoch of greater than 15 seconds of cumulative sleep in a 30 -second epoch. 
Trials are ended after 40 minutes if no sleep occurs, or after unequivocal sleep, defined as 3consecutive epochs of 
stage 1 sleep, or 1epoch of any other stage of sleep. If no sleep has been observed according to these rules, then 
the latency is defined as 40 minutes.
The secondary endpoints will be assessed through evaluation of the following parame ters: 
1.The following PK parameters calculated from plasma concentrations of TAK -925 and its metabolites M -I and 
M-II:
Area under the plasma concentration -time curve from time 0 to time of the last quantifiable concentration .
Area under the first moment plasma concentration -time curve from time 0 to infinity .
Maximum observed plasma concentration .
Plasma concentration observed at the end of infusion .
Time of first occurrence of C max.
Terminal disposition phase half -life.
Total clearance after intravenous administration (TAK -925 only) .
Volume of distribution during the terminal disposition phase after intravenous administration (TAK -925 
only).
Volume of distribution at steady state after intravenous administration .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 10of 91
Protocol Incorporating Amendment No. 01 08 May 2018
2.Sleepiness on the KSS.
Safety will be ass essed through the following parameters:
1.Treatment -emergent adverse events. Subjects will be monitored closely throughout the study for any adverse 
events .
2.Physical examinations.
3.Vital signs, including time -matched BP measurement and PK -BP relationships.
4. 12-lead ECGs.
5.Clinical laboratory safety evaluations (hematology, blood chemistry, and urinalysis).
6.Drug -
liking VAS.
7.POMS.
8.Continuous monitoring of BP, HR (eg, Bodyconnect) at time points specified in the protocol, and sleep cycle from 
Day -5 to -1 by  actigraphy with digital technology.
9. C-SSRS .
Statistical Considerations:
The effect of TAK -925 on sleep latency on the MWT will be evaluated with a mixed effects model appropriate for a 
4-period crossover study. The response variable in the model will be the o bserved value of sleep latency. The model 
will contain fixed effects for sequence, period, treatment (TAK -
925 LD, TAK -925 HD, modafinil, and placebo), time 
(as a categorical variable), and the treatment -by-time interaction, and a random effect for subject.
The estimated mean sleep latency for each treatment and the associated standard error and 95% CI will be extracted 
from the model at each time, along with all treatment differences and associated standard errors, 95% CIs, and 
p-values. The same quantities , averaged over all timepoints at which an MWT is performed, will also be extracted 
from the model using an appropriate contrast. The study objectives will be addressed using the results of the average 
treatment difference across all time points.
The change from time -matched baseline in HR and BP will be analyzed using a statistical model of the same form as 
for the primary endpoint. The estimated mean change from time -
matched baseline for each treatment and the 
associated standard error and 95% CI wil l be extracted from the model at each time, along with all treatment 
differences and associated standard errors, 95% CIs, and p -values. The same quantities, averaged over all postdose 
timepoints, will also be extracted from the model using an appropriate c ontrast.
Sample Size Justification:
The sample size justification is based on a similar study to assess the alertness -promoting effects of MK -0249, a 
histamine subtype -3 receptor inverse agonist, and modafinil 200 mg, in healthy sleep -deprived males [1]. In that 
study, investigators observed a mean increase in sleep latency in the MWT of  with modafinil 200 mg 
compared with placebo at 6 hours postdose and a within -subject standard deviation of approximately 6.74 minutes. 
With si milar variability, 16completers will provide approximately 90% power for detecting a difference in sleep 
latency in the MWT between TAK -925 and placebo if the true increase over placebo is . This result is based 
on a 2 -sided test with a .
To account for dropouts, approximately 20 subjects will be enrolled. 
CCI
CCI
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 11of 91
Protocol Incorporating Amendment No. 01 08 May 2018
1.1 Protocol Amendment 01 Summary of Changes
Rationale for Amendment 01
This document describes the changes in reference to the proto col incorporating Amendment 
No.01. The p rimary reason for Protocol Amendment No. 1 is to update cognition rat ing scales and 
revise protocol  text to align with the Inclusio n/Exclusio n Cri teria. Minor grammatical, editorial, 
and form atting changes are included for clarificat ion purposes only.
For specific descript ions of text changes and where the changes are located, see Appendix E.
Changes in Amendment 01 :
1.Removed Sustained Attention to R esponse Task (SART )assessment throughout protocol and 
updated study  schemat ic accordingly.
2.Replaced Cogstate Cognit ive Co mputerized Battery o f Tests wi th Cambridge Cognit ion 
Com puteri zed Battery  of Tests (CCBT) .
3.Updated alcoho l consumpt ion restrict ions.
4. U pdated caffeine consumpt ion restrict ions.
5.Updated smoking restrict ions.
6. Added dose levels selected for the low dose (LD) and high dose (HD).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 12of 91
Protocol Incorporating Amendment No. 01 08 May 2018
2.0 STUDY SCHEMATIC
Abbreviations: CCBT, Cambridge Cognition Computerized Battery of Tests; IV, intravenous; KSS, Karolinska 
Sleepiness Scale; MWT, maintenance of wakefulness test; NPSG, nocturnal polys omnography; PSG, 
polysomnogram.
*Performed once during the entire study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 13of 91
Protocol Incorporating Amendment No. 01 08 May 2018
3.0 SCHEDULE OF STUDY PROCEDURES
DayEach Treatment Period
Day Day Scheduled Time (Day 1 and 2) Day
-28
to -2 -1 Hours2 After 
Recovery 
Sleep 7
Screen -
ingdCheck
-inPre
doseAfter Start of Infusion After End of InfusionPost
dose/
Early
Termina -t
ionFollow
-up
Visit a
1 2 3 4 5 67 8 9 0.17 0.5 1 2 3 4 6 9
Administrative Procedures
Informed consent X
Inclusion/exclusion criteria X X
Medical history X X
Concomitant medication 
reviewX--------------------------------------------------------------- Continuous ------------- --------------------------------------------------------- X
Clinic 
Procedures/Assessments
Full physical examination X X bX X
Height X
Weight X X X X
Body mass index X
Vital signs (BP, HR) cX X X X X X X X X X X X X
Continuous monitoring with 
digital technology (BP, HR) d X X -------------------------------------------------------- Continuous ------------------------------------------------------------- X
Vital signs (respiratory rate, 
oral/tympanic temperature) e X X X
12-lead ECG eX X X X
Study  drug administration f9-hour continuous IV infusion
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 14of 91
Protocol Incorporating Amendment No. 01 08 May 2018
DayEach Treatment Period
Day Day Scheduled Time (Day 1 and 2) Day
-28 
to -2 -1 Hours2 After 
Recovery 
Sleep 7
Screen -
ingdCheck
-inPre
doseAfter Start of Infusion After End of InfusionPost
dose/
Early
Termina -t
ionFollow
-up
Visit a
1 2 3 4 5 67 8 9 0.17 0.5 1 2 3 4 6 9
C-SSRS X X X
Drug -liking VAS X
Actigraphy gX
Sleep deprivation XX--------------------------------------------------- --------------------------------
X
Adverse events monitoring X--------------------------------------------- Continuous ------------------------------------------- X
Pharmacodynamic 
Evaluations
Screening polysomnography 
(PSG)X h
Maintenance Wakefulness Test 
(MWT), power spectrum EEG i X X X X X X
Karolinska Sleepiness Scale 
(KSS) j X X X X X X
CCBT jX X X X X X
POMS kX X
Recovery sleep PSG X-----Continuous -----X
Laboratory 
Procedures/Assessments
Hematology X X X X
Urinalysis X X X X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 15of 91
Protocol Incorporating Amendment No. 01 08 May 2018
DayEach Treatment Period
Day Day Scheduled Time (Day 1 and 2) Day
-28 
to -2 -1 Hours2 After 
Recovery 
Sleep 7
Screen -
ingdCheck
-inPre
doseAfter Start of Infusion After End of InfusionPost
dose/
Early
Termina -t
ionFollow
-up
Visit a
1 2 3 4 5 67 8 9 0.17 0.5 1 2 3 4 6 9
Chemistry X X X X
Urine drug screenlX
Hepatitis screen X
HIV X
Blood for retained samples and 
pharmacogenomics h X
Pharmacokinetics 
Evaluations
Blood for plasma PK TAK -925 
andmetabolites assay m X X X X X X X X X X X X X X X
Other
Confinement X------------------------------------------------------------------ Continuous ---------------------------------------------------------------- X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 16of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Abbreviations: BP, blood pressure; CCBT, Cambridge Cognition Computerized Battery of Tests; C -SSRS, Columbia –Suicide Severity Rating Scale; EEG, electroencephalogram; 
HIV, human immunodeficiency virus; HR, heart rate; IV, intravenous; KSS, Karolinska Sleepiness Scale; MWT, Maintenance of Wak efulness; POMS, Profile of Mood States; PSG, 
polysomnography; PK, pharmacokinetics; VAS, visual analog scale.
aFollow -up visit will occur Day 7 (±2) after the last dose of study drugs.
bCan be performed within approximately 24 hours before study drug dosing.
cVital si gns (HR, BP) will be obtained as follows:
Day-1: will be obtained time matched with Day 1.Day -1 vital signs are to mirror the planned scheduled vital si gns for Day 1 as it relates to predose and postdosing scheduled vital 
signs. Predose and postd ose vit al signs at the identical times allows for a time-matched comparison.
Day1: predose, 1, 2, 4, 6, 9, 10, 11, 13 hours post IV dose
Follow -up visit
BP will be checked with the subject lying in a bed with the head of the bed at 30 degrees. See Section 6.2.4 for order of assessments.
dBP and HR will be continuously monitored during the confinement period, starting in the evening on Day -1.
eVital signs (other than HR and BP) and 12 -lead ECG will be performed within approximately 1 hour predose and 6 hour after start of infusion o n Day 1 and at discharge on Day 2.
fModafinil or matching placebo capsule will be administered at approximately an hou r before start of IV dosing on Day 1. TAK -925 or matching placebo will be started infusing 
approximately at 11:00 PM on Day 1.
gSubjects will be monitored with actigraphy from Day -6 through Day -1.
hWill be performed only once in each subject before tre atment period 1.
iMWT will be performed as following; approximately 2, 4, 6, 8, 10 hours after start of IV infusion. The MWT done at approximat ely 10 hours will be appr oximately 1 hour and 
20minutes after the end of the drug infusion. A practice MWT session will be performed on Day 1 of treatment period 1 (only once during the entire study) to familiarize subjects with 
the procedure.
kThe POMS will be done predose to modafinil/placebo or IV drug administration and after the last MWT and KSS, and CCBT have been completed.
lUrine drug screen will be done at first period only, and not subsequent periods.
mBlood for TAK -925 PK will be collected: Pre, 1, 2, 4, 6, and 9 hours after start of infusion; 0.17, 0.5, 1, 2 , 3, 4, 6, 9 hours after end of infusion; and at discharge. 
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 17of 91
Protocol Incorporating Amendment No. 01 08 May 2018
4.0 INTRODUCTION
4.1 Background
Orexin (OX) is a neuropeptide that was discovered independent ly by research groups in Japan and 
the United States . The orexinergic system is a major wake -prom oting system  of the brain. 
OX-producing neurons are localized in a specific region of the lateral hypothal amus and have 
excitatory  projections to wide areas of the neuraxis, including the cerebral cortex and other 
wake -prom oting nuclei (cho linergic neurons of the basal forebrain, tubero mammillary nucleus, 
locus coerul eus, ventral  tegm ental  area and dor sal raphe nucleus). The orexinergic system is also 
involved in several other funct ions, such as feeding, reward, and sympathet ic act ivity. Two 
orexinergi c neuropepti des, orexin -A and o rexin -B, have been ident ified to date. The orexins exert 
effects via 2 t ypes of receptors ;orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). 
Orexin -A has a high affinit y to OX1R and OX2R, and orexin -B has a high affinit y to OX2R. The 2 
OXreceptors have a dist inct distribut ion in the arousal network –the locus coeruleus contains only 
OX1R, the tuberomammillary nucleus only OX2R, whereas both receptor types occur in the dorsal 
raphe nucleus andventral  tegm ental  area . The 2 OXreceptors make dist inct contribut ions to the 
regul ation of arousal. OX2R in the tuberom ammillary  nucleus are essential for the maintenance of 
wakefulness (MWT) , whereas both receptor ty pes are requi red for the inhibi tion of  rapid eye 
movement (REM) sleep [
2].
The pathological loss of orexinergic neurons is associated with the development of narcolepsy [3]. 
The symptoms of narco lepsy can be divided into 2 groups: (i)symptom s caused by the intrusion o f 
non
-REM sleep into wakefulness (excessive day time somnolence[EDS], sl eep attacks) and (ii) 
symptoms caused by  the intrusi on of  REM sl eep into wakefulness (c atapl exy, hypnagogi c or 
hypnopom pic hallucinations, sleep paralysis) [2]. The REM –sleep -related symptom s reflect 
physio logical acco mpaniments of REM sleep: loss of muscle tone (cataplexy, sleep paralysis) and 
dreaming (visual hallucinat ions). 
Narcol epsy can also occur wi thout catapl exy, termed narcol epsy t ype 2 (NT2); patients with this 
disorder m ay exhibi t all clinical  features of narco lepsy with the except ion of cataplexy [4]. 
Narcol epsy with catapl exy, or narcol epsy type 1 (NT1), has been defined by  Internati onal 
Classificat ion of Sleep Disorders, 3rd editio n (ICSD -3) cri teria as having l ow levels o f OX in 
cerebrospinal fluid (CSF) (<110 pg/mL; <30% of normal levels) and narco lepsy wit hout cataplexy 
(NT2) with CSF OX levels >110 pg/mL (at least 30% of normal). 
Thepathophysio logyofNT1 has a presum ed, thoug h unproven, autoimmune basis in individuals 
with a specific genet ic predisposit ion, the most commo n of which is the HLA DQB1*0602 (HLA 
DQB1 [m ajor histocom patibilit y complex, class II, DQ beta 1
]) [5,6]. The proposed etiol ogy 
involves T -cell mediated destruction of OX -producing neurons in the hypothalamus 
[6-8] . Loss of OX- producing neurons are reflected by low CSF OX levels [9]. 
The presumed pathophysio logy of NT2 i s unclear. However, there are examples of pat ients 
initially classified as having NT2 who later develop cataplexy. In a few pat ients, CSF levels of OX 
have been demo nstrated to decrease over time [
10].The dichotomy of the ICSD -3 criteria have 
also been su bject to som e criticism since m easurement of OX in CSF is only  perf ormed as a 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 18of 91
Protocol Incorporating Amendment No. 01 08 May 2018
research tool and is not c linically available, and the symptoms of cataplexy may be quite subt le 
and unrecognized. As many as 30% of pat ients with NT2 are found to have CSF OX levels that are 
lower than normal [11]. African Americans are more likely to have low OX levels, even if 
cataplexy  is absent [
12]. It may be that there is a spectrum of narcolepsy  such that som e OX l oss 
resul ts in EDS wi thout catapl exy, whereas greater loss results in cataplexy. This concept of a 
narco lepsy spectrum  is supported by  murine m odels of  narco lepsy that show greater hy pocretin 
loss in animals exhibit ing cat aplexy than in those exhibit ing only sleep fragmentation/wakefulness
[11].
Mild to moderate loss of OX neurons has also been shown to occur in several neurodegenerat ive 
diseases (60% in Parkinson’s disease, 40% in Alzheimer’s disease, and 30% in Hunt ington’s 
disease, in contrast to 90% in narcolepsy) and this may contribute to th e EDS observed in so me 
patients wi th these diseases.
Current
ly available medicat ions for EDS include modafinil, methylphenidate hydrochloride, 
dextroam phetamine sulfate, and/or sodium oxybate. These drugs have limited effect iveness and/or 
undesirable side effects such as nausea, headache, and dizziness [13]. The adverse effects fro m 
amphetamines also include irritabilit y, hyperact ivity, trem or, and m ood changes [14]. Based on 
the data described above demonstrati ng that partial or complete O
Xdeficiency plays an important 
role in the development of EDS, OXreplacement therapy is expected to improve EDS through the 
pathophysio logy-directed m echanism  of action (MOA). A novel drug that acts to help address the 
deficiency of OXmay address the spectrum  of narcol epsy symptoms, and may  have greater 
efficacy  than currently approved drugs for treatment of EDS.
TAK -925 i s a highly selective OX2R agonist being developed by Takeda for the treatment of 
narco lepsy. The OX receptor i s a G protein -coupl ed re ceptor that has 2 subt ypes, OX1R and 
OX2R. Upon activat ion, OX1R and OX2R couple with Gq protein to increase intracellular
calcium (Ca2+)concentration. In Chinese hamster ovary  K1 cells expressing recombinant human 
OX2R, TAK -925 increased intracellular Ca2+levels in a concentration dependent manner. In vivo  
pharmaco logy studi es have demo nstrated that TAK 925 increased wakefulness and decreased 
cataplexy -like events in the OX/ataxin- 3 mouse model  of NT1. TAK -925 significant ly and 
dose-dependently enhanced wakefulness in wild t ype (WT ) mice, commo n marmosets, and 
cyno molgus monkeys. Please refer to the TAK -925 Invest igator’s Brochure for complete 
inform ation on the invest igational product.
4.2 Rationale for the Proposed Study
TAK -925 showed arousal effects in WT mice and mo nkeys as well as in OX/ataxin -3 mice, a 
narco lepsy mouse m odel with a loss of  OX-producing neurons. This strongly  suggests that 
TAK -925 can st imulate the OX wake promoting system, even if it is not deficient. It is important 
to note that the ef fects in the WT animals were found during their “sleep phase”. OX levels vary 
across the diur nal cycle [15,16] , lowering midnight to early morning in the squirrel monkey, whic h 
has a pattern of wakefulness similar to that of humans [
15]. As rigorous translat ion of an imal 
models to the human condit ion is crit ical to our understanding of drug mechanisms in this study, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 19of 91
Protocol Incorporating Amendment No. 01 08 May 2018
TAK -925 will be administered to sleep -deprived heal thy subjects during nighttime to evaluate 
effects on wakefulness in sleep phase (see Figure 4.a) [15]. 
Figure 4
.a Model of Diurnal Intrinsic OX Level in Brain Over Time
4.3 Benefit/Risk Profile
As thi s study will be conducted in healt hy subjects, there is no expected clinical benefit to study
participants other than receiving medical examinatio ns and informat ion about their overall healt h 
condi tions. It is possible tha t the informat ion obtained in the present study  will become beneficial 
to patients with narco lepsy in the future.
This phase 1 study has been designed to mit igate the potential risks based on nonclinical findings. 
In addit ion, there is minima l risk associa ted with study noninvasive procedures including vital sign 
assessments and electrocardiograms (ECGs).
The principal mit igation for these ri sks includes appropriate select ion of the study popul ation, the 
clinical research unit setting, which permit s close m onitoring and rapi d inst itution of appropriate 
care as needed, appropriate specified monitoring procedures, and utilizat ion of experienced staff 
trained in study procedures. Overall, the risk:benefit profile is considered appropriate for this 
study .
4.3.1 TAK -925
TAK -925 safet y informat ion is derived fro m the data obtained fro m nonclinical studies and 
preliminary data fro m the ongoing first -in-human (FIH) study  TAK -925-1001 in Japanese 
subjects.
Risks observed during the nonclinical studies included convulsio ns, vomiting, and blood pressure 
(BP)increase. Convulsio ns were observed in a single -dose intravenous ( IV)escalat ing 
administration toxicit y study  in monkeys at a high infusio n rate, but were not observed in 2- week 
Good Laboratory  Practi ce toxicol ogy studi eswith a slower infusio n rate. Vomit ing was seen in 
2-week toxicology studies in animals given higher doses. Nausea and vo miting are readily  
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 20of 91
Protocol Incorporating Amendment No. 01 08 May 2018
monitored in subjects and managed as appropriate , incl uding potenti ally stopping the study  drug 
infusio n. A mean sys tolic blood pressure (SBP) increase up to 19 mmHg was also noted in a 
monkey safet y phar maco logy study, and based on published literature this is considered a potential 
mechanism -based risk for OX2R agonists [17]. Therefore , frequent BPmeasurements will be 
obtained throughout the study . Detailed pl ans f or management of BPincrease are in Sect ion7.6.
 
As the drug is expected to have a short half -life, stopping the infusio n shoul d resul t in rapi d BP
lowering if tol eration does not dev elop wi th continued study  drug infusi on.
The FIH phase 1 study of TAK -925, TAK -925- 1001 is current ly being conducted in Japan. It is 
assessing the safet y, tolerabilit y, pharmacokinet ics (PK), and pharmacodynamics (PD) of a single 
9-hour IV dose of TAK - 925 when administered to healt hy adult and elderly  adul t volunteers and 
patients wi th narcol epsy. This study  consists of 2 parts: Part 1 and Part 2.
Part 1 i s an al ternat ing panel, rando mized, double -blind, pl acebo -controlled, dose -escalat ion, 
crossover study  to assess the safet y, tolerabilit y and PK of TAK -925 when administered as a 
single- dose to heal thy adul t and el derly adul t volunteers. In Part 1, the safety , tolerabili ty and the 
PK including the concentration o f TAK -925 in the CSF when administered as a s ingle dose to 
healt hy adult vo lunteers will also be evaluated in a unblinded fashio n.
Part 2 i s a sequent ial panel , randomized, double -blind (sponsor unblinded), placebo -controlled, 
2-period crossover study  to assess the safet y, tolerabilit y, PK, and PD of 1 or more doses of 
TAK -925 versus placebo in patients with NT1.
In Part 1, In the ongoing FIH study TAK -
925-1001, single doses of TAK -925 or matching placebo  
given IV for 9 hours have been administered in Part 1 to 16 subjects (12 active and 4 placebo) in
2cohorts in an alternating panel design. Cohort 1 received 7, 28, and 112 mg TAK -925/placebo as 
single doses and Cohort 2 received 14, 56, and 134.4 mg TAK -
925/placebo as single doses in 2 
treatm ent peri ods, wi th a washout peri od of  at least 7 days. Foll owing review of the safet y, 
tolerabilit y, and PK in these cohorts, 6 healthy  elderly  adul t subjects received a single IV dose of 
112mg TAK -925 and 2 subjects received placebo. Cohort 4 will assess the safety and tolerabilit y, 
and PK of TAK -925 including t he concentration of TAK -925 in the CSF in 4 healt hy adult s.
TAK -925 was safe and tolerable in dose range tested betw een 7 mg and 134.4 mg (as of 
19February 2018). PK parameters showed dose proportional increases wit h a relatively lo nger 
half-life (approxi mately 3 to 5 hours) in man than in animals.
A total o f 16 subjects were init ially dosed; however, in the first cohort (7 mg/placebo), 1 subject 
experienced a headache, and withdrew fro m the study . This subject was l ater di agnosed wi th 
influenza (headache included under symptom term). Subsequent cohorts that included that panel 
had 7 rather than 8 subjects. No other subject withdrawals have occurred. There have been no 
serious adverse events ( SAEs )or severe adverse events (AEs) .
All AEs except influenza (c onsidered as moderate) were mild in severit y. All cardi ovascular 
effects related AEs (BP increased, pulse rate increased) were considered as mild.
A summary  of blinded treatm ent-emergent adverse event (TEAE) data (verbat im terms) reported 
in Cohorts 1 and 2 (healthy adult subjects) and Cohort 3 (healthy elderly adult subjects) in 
Study TAK -925- 1001 i s provi ded in  Table 4.aand  Table 4.b, respectively.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 21of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Table 4.a Summary of Blinded TEAE Data From Study TAK -925- 1001 
(Cohorts 1and 2, Healthy Adult Subjects a)
Verbatim TermNumber of Events
Part 1 SRD Cohorts 1 -2
TAK -925 or Placebo
(Healthy Adultsa)
7mg
n=814mg
n=828mg
n=756mg
n=8112mg
n=7134.4 mg
n=8
Any TEAE 2 0 1 3 1 7
Orthostatic hy potension 1 0 0 0 0 0
Influenza 1 0 0 0 0 0
Electrocardiogram PR prolongation 0 0 1 0 1 0
Pharyngodynia 0 0 0 1 b0 0
White blood cell count increased 0 0 0 1 0 0
Triglyceride increased 0 0 0 1 0 0
Pulse rate increased 0 0 0 0 0 3
Blood pressure increased 0 0 0 0 0 2
Nausea 0 0 0 0 0 1
Feeling drunk 0 0 0 0 0 1
Abbreviations: SRD, single rising dose; TEAE, treatment -emergent adverse event.
a.Aged 20 to 55 years, inclusive.
bPredose.
Table 4.b Summary of Blinded TEAE Data From Study TAK - 925-1001 (Cohort 3, 
Healthy Elderly Adult Subjectsa)
Verbatim TermNumber of Events
Part 1 SRD Cohort 3
TAK -925 or Placebo
112mg
(Healthy Elderly Adults a)
n=8
Any TEAE 4
Blood pressure increased 4
a.Aged 65 to 80 years, inclusive.
Please refer to the TAK -925 Invest igator’s Brochure for available clinical informat ion on the 
investigat ional product.
4.3.2 Modafinil
Modafinil is approved in the United States as Provigil and name brand drug will be supplied for 
thisstudy . The m ost seri ous ri sks noted in the prescribi nginformat ion are noted below.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 22of 91
Protocol Incorporating Amendment No. 01 08 May 2018
There i s a very  low ri sk of  serious rash, which m ay requi re hospi talizat ion and di sconti nuati on of  
treatm ent in adults in association wit h the use of modafinil. Therisk is even lower with only 1 dose 
of the drug. The full pre scribing informat ion notes that no serious skin rashes have been reported 
inadult clinical  studi es (0 per 4 264) of modafinil . Rare cases of seri ous or life -threatening rash, 
including Stevens -Johnson syndro me, toxic epidermal necro lysis, and drug rash wit h eosinophilia 
and systemic s ymptoms have been reported in adults and children in worldwide post market ing 
experience. The reporting rate of toxic epiderm al necrolysis and Stevens -Johnson syndrome
associ ated wi th modafinil  use, which is generally accepted to be an underest imate due to 
underreporting, exceeds the background incidence rate. 
There are no factors that are known to predict the risk of occurrence or the severit y of rash
associ ated wi th modafinil . Nearly  all cases of serio us rash associated with m odafinil occurred 
within 1 to 5 weeks after treatment init iation. Although benign rashes also occur with modafinil, it  
is not possible to reliably  predict which rashes will prove to be serious. Accordingly, modafinil 
shoul d ordinarily  be di scontinued at th e first sign of rash, unle ss the rash is clearly not 
drug-related. Discontinuation of treatment may not pr event a rash fro m beco ming life -threatening 
or perm anent ly disabling or disfiguring.
One serious case of angioedema and 1case of hypersensit ivity (wi th rash, dysphagia, and 
bronc hospasm), were observed amo ng 1595 patients treated with armodafinil, the R-enant iomer of 
modafinil (which is the racemic mixture). No such cases were observed in modafinil clinical 
studi es. However , angi oedema has been reported in postmarket ing experience wit h modafinil.
Multi-organ hypersensit ivity react ions, including at least 1 fatality in post marketing experience, 
have occurred in close temporal associat ion (median time to detection 13 day s: ran ge4-33) to the 
initiation of modafinil. Although there have been a l imited number of reports, mult i
-organ 
hypersensit ivity react ionsmay resul t in hospitalization or be life -threatening. There are no factors 
that are known to predict the risk of occurrenc e or the severit y of multi-organ hypersensit ivity 
reacti ons associ ated with modafinil . If a multi-organ hypersensit ivity reacti on is suspected, 
Provi gilshoul d be di scontinued.
In the adult modafinil controlled trials database, psychiatric symptoms result ing in treatm ent
discontinuat ion (at a frequency >0.3%) and reported more often in patients treated with modafinil 
compared to those treated with placebo were anxiety  (1%), nervousness (1%), inso mnia (<1%), 
confusio n (<1%), agitation (<1%), and depressio n (<1%). Caution should be exercised when 
Provi gilis given to patients with a history  of psychosis, depression, or mania.
BPmonitoring in short -term (<3 months) controlled trials showed no clinically significant changes 
in mean SBP and diastolic blood press ure (DBP) in patients receiving Provi gilas co mpared to 
placebo.
Please refer to the current package labeling for modafinil for detailed informat ion regarding the 
safet y risks and ri sk mi tigation measures for m odafinil.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 23of 91
Protocol Incorporating Amendment No. 01 08 May 2018
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objec tives
5.1.1 Primary Objective
1. To determine the effect of TAK- 925 after a single IV dose (compared to placebo) on 
prom oting wakefulness as measured by  sleep l atency  on the MWT (performed at 
approximately  2, 4, 6, and 8 hours post -dosing starting at approximately  1:00 AM an d then at 
approximate times of 3:00, 5:00, and 7:00 AM) in sleep -deprived healt hy vo lunteers. 
Hypothesis : At l east 1 of the tested doses of TAK -925 is superior to placebo for promoting 
wakefulness as measured by  sleep latency  on the MWT (a diffe rence between TAK -925 and 
placebo of 9 minutes or greater is est imated).
5.1.2 Secondary Objectives
1.To assess the safet y/tolerabilit y and PK parameters of a single IV infusio n of TAK -925 in 
sleep -deprived healt hy vo lunteers.
Hypothesis : TAK -925 is generally well tolerated when administered as a single IV infusio n, 
including effects on BP. (Overall mean difference in t ime-matched BP increase fo llowing 
administration of safe, tolerable, and effect ive dose of TAK -925 i s less than or equal to 
10mmHg over placebo.)
2. T o determine the effect of a single dose of m odafinil  (300 m g) on prom oting wakefulness as 
measured by sleep latency on the MWT in order to confirm assay  sensi tivity.
Hypothesis : Modafinil (300 mg) is superior to placebo on promoting wakefulness as measured
by sleep latency on the MWT (a difference between modafinil and placebo of 9 minutes is 
estimated [18].
3.To evaluate the effect of TAK -925, 44mg (low dose [LD]) and 112mg (high dose [HD
]), on a 
measure of sleepiness, as compared to placebo.
Hypothesis : At l east 1 do se of TAK -925 will be superi or to pl acebo on the Karolinska 
Sleepiness Scale ( KSS).
5.1.3 Exploratory Objectives
In sleep -deprived healt hy volunteers: 
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 24of 91
Protocol Incorporating Amendment No. 01 08 May 2018
5.2 Endpoints
5.2.1 Primary Endpoint
1.Latency for e ach MWT, defined as time to sleep onset.
Sleep onset is defined as the first epoch of greater than 15 seconds o f cumulat ive sleep in a 
30-second epoch. Trials are ended after 40 minutes if no sleep occurs, or after unequivocal 
sleep, defined as 3 consecut ive epochs of stage 1 sleep, or 1 epoch of any other stage of 
sleep. If no sleep has been observed according to these rules, then the latency is defined as 
40 minutes.
5.2.2 Secondary Endpoints
Secondary  endpoints will be assessed through the following parameters :
1.The fo llowing PK parameters calculated fro m plasma concentrati ons of TAK -925 and i ts 
metabo lites M -I and M -II:
Area under the plasma concentration -time curve from time 0 to time of the last quantifiable 
concentration (AUC last).
Area under the first mo ment plasma concentration -time curve fro m time 0 to infinit y 
(AUC ∞).
Maximum observed plasma concentration (C max).
Plasma concentration observed at the end of infusion (C eoi).
Time o f first occurrence of C max(tmax).
Terminal disposit ion phase half -life (t 1/2z).
Total  clearance after intravenous administration (CL) (TAK -925 only).
Volume of distribut ion during the terminal dispositio n phase after intravenous 
administration (V z)(TAK -925 only).
Volume of distribut ion at steady  state after intravenous administra tion (V ss).
2.Sleepiness on the KSS.
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 25of 91
Protocol Incorporating Amendment No. 01 08 May 2018
5.2.3 Safety Endpoints
Safety will be assessed through the fo llowing parameters:
1.TEAEs. Subjects will be monitored closely  throughout the study  for any  AEs.
2.Physical examinat ions.
3.Vital signs, including time -matched BP measurement and PK -BP rel ationships.
4. 12- lead ECGs.
5.Clinical laboratory  safet y evaluat ions (hematol ogy, bl ood chemistry , and urinalysis).
6.Drug -liking visual analog scale ( VAS )
.
7.Profile of Mood States ( POMS ).
8.Continuous monitoring of BP and heart rate ( HR),eg, Bodyconnect ,at time points specified in 
the protocol, and sleep cy cle fro m Day -5 to -1 by actigraphy  with digital technol ogy.
9.Columbia -Suicide Severit y Rating Scale ( C-SSRS ).
5.2.4 Exploratory Endpoints
Exploratory  endpo ints will be assessed through the f ollowing param eters:
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 26of 91
Protocol Incorporating Amendment No. 01 08 May 2018
6.0 STUDY DESIGN AND DESCRIPTION
6.1 Study Design
This is a rando mized, double -blind, do uble-dummy , placebo -and active -controlled, 4- period 
Williams design crossover study to evaluate the PK, PD, and safet y of TAK -925 in sleep -deprived 
healt hy vo lunteers. TAK -925 will be administered as an IV infusio n over a 9 -hour period based on 
the safet y/tolerabilit y and PK profiles established in healt hy Japanese subjects in ongoing 
Study TAK -925-1001.
Healthy adul t male subjects aged 18 to 40 y ears, incl usive, who sati sfy inclusi on and exclusio n 
criteria will be enro lled in the trial. Approximately 20 s ubjects will be enrolled to ensure that at 
least 16 subjects complete the study . 
On Day 1of treatm ent peri od 1, eligible subjects will be equally rando mized to 4 treatm ent 
sequence groups (Sequence 1 to 4) which define the order of the treatment administ ration 
(TAK -925 LD mg, TAK -925 HD mg [ both de livered as a 9 -hour IV infusio n], modafinil 300 mg, 
and placebo )
.
A summary  of the study  drug assignment and sequence in presented in Table 6.a.
Table 6.a Summary of Study Drug Assignment and Sequence (Double Dummy for 
Placebo)
Sequence N Period 1 Period 2 Period 3 Period 4
1 5 TAK -925 LD mg Placebo TAK -925 HDmg Modafinil 300 mg
2 5 TAK -925 HDmg TAK -925 LDmg Modafinil 300 mg Placebo
3 5 Modafinil 300 mg TAK -925 HDmg Placebo TAK -925 LDmg
4 5 Placebo Modafinil 300 mg TAK -925 LDmg TAK -925 HDmg
Abbreviations: HD, high dose; LD, low dose.
At the screening visit, subjects will complete medical examinat ions, an electrocardi ogram  (ECG ), 
and clinical laboratory  tests. After the screening visit, eligible participants will wear an act igraph 
from Day -6 until Day -1. After validat ion that actigrap hy a normal sleep -wake cycle, and subjects 
have a negat ive drug screen, subjects will undergo an 8 -hour nocturnal po lysomography  (NPSG )
to exclude any sleep disorders. Act igraphy results will also be co llected for the 5 -night period 
before Day-1 (Day -6 toDay -1) for every treatment period to ensure that sleep falls wit hin norma l 
nocturnal  times (defined under Inclusio n Cri teria).
During the day  beforedosing on Day  1, parti cipants will be administered the KSS and CCBT at 
scheduled timepo ints. A practice M WT s ession, as well as one practice CCBT , will be performed 
on Day 1 Treatment Period 1 (only  once during the entire study ) to f amiliar ize subjects with the 
procedures . Study drug will be administered in the clinic in the evening on Day 1 of each treatment
period. Subjects will undergo the MWT, KSS, and CCBT at specified time points after the start of 
the infusion. Subjects will be required to stay  awake in between the MWT tests. Following 
completion of the IV infusio n on Day  2, subjects will  undergo an additional MWT test. When the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 27of 91
Protocol Incorporating Amendment No. 01 08 May 2018
final MWT test and cognit ive testing have been completed, subjects will be allowed t o sleep 
(recovery  sleep) for approximately 6 hours. PSG recording will be collected during this time. 
Subjects m ay be di scharged from  the uni t after complet ion on Day 2 with continuing act igraphy 
upon discharge (to begin on Day  -6 before the next treatment period). The interval of each 
subsequent treatment period will be at least 7 days to assure that the subject ’s circadian rhyt hm has 
returned to a norm al cycle. Subject’s vital s igns, including BP , will be cont inuously mo nitored 
during the dosing and testing period. Blood samples for determination o f TAK -925 pl asma 
concentrations will be co llected at specified timepoints on Day s 1 and 2 of each trea tment peri od. 
Subjects will co mplete the C -SSRS during Screening, before study  drug administrati on, and 
before discharge on Day  2 of each treatment period. Subjects will co mplete the POMS before and 
post study  drug administrati on, and undergo a drug -likingVAS f ollowing recovery  sleep in each 
treatm ent peri od.
An overview of the dosing and sampling scheme is provided in Table 6.b.
Table 6.b Dosing and Sampling Scheme
Screening PeriodCheck -
in and 
BaselineTreatment Period Time Interval 
Between 
Subsequent 
Treatment PeriodDose/Sample 
Collection Sample Collection
Days -28 to -2 Day -1
NPSG/BP 
measurement aDay 1
Sleep 
deprivation/study 
drug 
administration/study 
assessmentDay 2
Sleep 
deprivation/study 
drug continued 
infusion/study 
assessment/recovery 
sleepMinimum of 7 day s 
with actigraphy for 
5days
X--------------------------- Confinement ----------------- ----------- X
Abbreviations: BP, blood pressure; NPSG, nocturnal polysomnography.
aNPSG and time -matched BP only on Day -1 of treatment period 1. For Periods 2, 3, and 4, subjects will be admitted 
to the unit and allowed to sleep normally without NPSG or time -matched BP measurement. The time interval from the 
end of 1 period to the star t of the next period will be at least 7 days.
6.2 Rationale for Study Design, Dose, and Endpoints
6.2.1 Rationale of Study Design
The study populat ion chosen for this study consists of males aged 18 to 40 years who are generally 
in good health and normotensive (see inclusio n/excl usion cri teria for specifics). Heal thy males
only are being used in this study  to minimize any inter -and intra -individual variabilit y related to 
between gender effects of the sleep cycle, as well as potential effects of the menstrual cycle o n 
sleep. The age range specified is to again to mit igate against any effects of older age on sleep, as 
well as the higher likelihood of sleep abnormalit ies that rises with increasing age. This cohort is 
similar to that in other invest igationaldrug studi eswith sleep deprivat ion in healthy normal  
subjects.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 28of 91
Protocol Incorporating Amendment No. 01 08 May 2018
This 4 -period, Williams design crossover study  is a design that has been previously used in other 
studi es of  drugs that have been evaluated for effects on wakefulness [18]. While there is a risk of 
dropouts during the study , a rel atively short time between periods will aid in subject retention. A 
crossover design requires fewer subjects than a parallel group design, as treatment comparisons 
are based on intra -subject differences which a re typi cally associ
ated wi th smaller vari ability than 
between -subject differences. The study  is directly translat ional fro m the data obtained in normal 
animals including 2 species of non- human primates. 
Nighttime is considered the most appropriate time pe riod to eval uate the efficacy of TAK -925 in 
this sleep -deprived m odel study  since there is evidence that OX levels are relat ively lower during 
the nighttime co mpared to dayt ime. Considering the MOA of TAK -925, i t is a reasonable 
assumpt ion that the sensit ivity to detect the efficacy of TAK -925 in healt hy normal persons should 
be greater during nighttime.
Moda finil 300 mg, a standard treatment for EDS, will be included as an act ive reference 
compound. Modafinil is one of the most comm only used stimulants fornarcolepsy, 
hyperso mnolence associated with obstructive sleep apnea and shift -work disorder . Modafinil has 
previously been evaluated in both narcolepsy studies [19] and in sleep deprivat ion stud iesin 
healt hy vo lunteers[
20]. The tmax of modafinil is approximately 3hours and in sleep -deprived 
healt hy vo lunteers, MWT or efficacy on cogni tive tests has been detected at approximately tmax
post administration. Compared withplacebo, m odafinil showed greater effects on wakefulness on 
the MWT sleep latency in both sleep -deprived healthy  volunteers andin narco lepsy pat ients, with
9-minute and6-minute increases in sleep latency , respect ively [1,21]. Modafinil lose sits PD 
effect sat 10hours post dosing ,which is close to the same durat ion of the 9- hour TAK -925 
infusi on. The timing o f thedose of modafinil will be given so that tmaxis achieved at the time of the 
first MWT . Modafinil will be given 1 hour before the start of the IV infusio n.The study  is not 
powered for use of modafinil as an actual comparator compound.
A double- dummy desig n will be used. Subjects receiving modafinil wi ll receive IV normal saline . 
Those receiving TAK -925 will be given an oral (PO) placebo capsule.
6.2.2 Rationale for Dose
Based on the currently available informat ion, this study will evaluate 2 dose levels of TAK -925, a 
low dose of 44 mg ( LD)and high dose of 112 mg (HD). The HD of 112 mg was selected based on 
the safet y and tol erabili ty resul ts in adult subjects from the ongoi ng FIH TAK -925-1001 study . 
Doses up to and i ncluding 134.4 mg, the maximum dose tested so far in healt hy volunteers, were 
safe and well tolerated with no severe AEs or SAEs . All subjects dosed with 112 mg TAK -
925had 
acceptable safet y and tol erabilit y during the 9-hour IV infusio n. The 44mg LD was selected to 
evaluate a dose that mayresul t in effects on wakefulness (as assessed by the MWT) that are greater 
than those of
placebo, based on nonclinical studies, but are associated with systemic exposures of 
TAK -925 that are pharmaco logically  different those expected at the HD of 112 m g. Based on
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 29of 91
Protocol Incorporating Amendment No. 01 08 May 2018
 
 
 
. Thus, the potential d ifference in the 
pharmaco logical response to TAK -925 has also been taken into considerat ion when choosing the 
LDand HDin sleep -deprive d heal thy subjects .
6.2.3 Rationale for Endpoints
6.2.3.1 Primary Endpoint
Effect on wakefulness as measured by sleep latency on the M WT was selected as the primary 
endpo int. The MWT is a validated objective measure that has been often used as a primary efficac y 
endpo int to m easure EDS in clinical studies. An approximate 9- minute increase over placebo is 
considered as a benchmark PD effe ct size of TAK -925 in this study , based on the efficacy of 
modafinil 200 mg in a similar study in asleep -deprived healt hy population [18].Note that the dose 
of modafinil  used in this study  will be 300 m g, which has been selected to d emonstrate assay 
sensit ivity.
6.2.3.2 Secondary Endpoints
KSS
The KSS is helpful in assessing the changes in response to the effects of drugs and is a measure o f 
situational sleepiness. It is sensit ive to fluctuations. It has been used in studies of shift work, je tlag, 
for driving abilit ies, attention and performance, and in clinical settings. It is helpful in assessing 
the changes in response to environmental factors, circadian rhyt hm, and effects of drugs. In a study 
conducted by  [22,23] the authors invest igated the validit y of the KSS and found that it was highly 
correl ated to EEG and behavioral variables. The results show that KSS has a high validit y. 
CCBT
The CCB Thasbeen used in studies on sleep depr ivation and shift work- related cognit ive 
impairment and the potential for detection of pharmacological remediation hasalso been evaluated
(internal data, Cambridge Cognit ion). Reaction time related batteries in the CCBT have show n
significant deterioratio n with sleep deprivat ion[24-26] .
Wearable Devices
Wearable digi tal devices will be implemented in this study for monitoring bio metri c and physical 
activit ies associated with the sleep -wake cycle. An actigraphy device will capture data on the 
subject’s activit y level, including intensit y of movem ent, rest, and sleep. The primary purpose of 
thisdata is to confirm that the subject hasmaintained normal sleep/wake life habits beforestudy  
drug administration. 
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 30of 91
Protocol Incorporating Amendment No. 01 08 May 2018
BP data will be collected using a wrist -or finger -based device for measurement of radial arterial 
pressure or digita l arteri al pressure. BP data will be collected during PSG monitoring and 
continuous drug infusio n to provide ample data for evaluat ion of PK -PD rel ationships between 
TAK -925 and BP versus placebo and BP. Outcome of these PK -PD analys es will  help to inform  
assessment of the effects of TAK- 925 on BP.
6.2.3.3 Exploratory Endpoints
6.2.3.4 Safety Endpoin ts
The safet y endpo ints of TEAEs, vital signs, 12 -lead ECGs, and clinical laboratory evaluations 
(including hematology , chemistry , and urinalysis) are standard methods for assessing safet y and 
tolerabilit y of drugs in clinical studies.
The drug- liking VAS is a standard tool for assessing drug abuse potential. Many st imulant drugs 
are scheduled substances based on the potential for abuse. While TAK -925 i s early  in 
development, it is important to begin assessing the potential for abuse. An assessment of drug 
liking will be included. Since, TAK -925 has central nervous system (CNS) activit y in animals and 
is expected to have CNS activit y in humans, abuse potential will be assessed. TAK -925 is 
theorized to have a low potenti al for abuse probabilit y based on its h igh select ivity for OX2R over 
OX1R [
28]. Preliminary informat ion relevant to the potenti al for abuse could be informative for 
further development of TAK-925.
The POMS is a well -validated self -report m easure of m ood s tates, and has high internal 
consistency as well as predictive and constructive validit y. POMS is used in many clinical studies 
including research in narco lepsy populat ions[29].
Subjects will be mo nitored for any  signs of suicidal ideation or behaviors using the C
-SSRS.
BPincrease isanident ified riskfromnonclinical safetystudi es.IntheFIHstudy
(TAK -925- 1001), mild BPincrease orHRincrease were reported in2healt hynorm alsubjects out
of8subjectsatthe134.4 mgdose levelduring study drug infusio n.Continuous BPmeasurements
willbeobtained inthisstudy tofurther characterize PK-PDrelationships withanyBPincrease that
may beobserved afteradministration ofTAK -
925.
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 31of 91
Protocol Incorporating Amendment No. 01 08 May 2018
6.2.4 Critical Procedures Based on Study Objectives: Timing of Procedures
For thi s study , the MWT is the crit ical procedure and should be performed as close to the 
scheduled time as possible.
Blood sam ples f or PK evaluat ions must be drawn as close as possible to the specified t ime.
ECG and vital sign measurements should be completed before blood sampling if the t iming o f 
these assessments overlap.
All other procedures should be performed as close as possible (either before or after) the 
scheduled times.
The suggested order of the PD assessments of each treatment period is as fo llows:
–MWT .
–KSS.
–CCBT .
–POMS .
The order of priorit y can be changed during the study with joint agreem ent of  the invest igator 
and the sponsor.
Any nonscheduled procedures required for urgent evaluat ion of safet y concerns take 
precedence over all routine scheduled procedures.
6.3 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
Modificat ions to the dose, dosing regimen, and/or clinical or laboratory  procedures currently  
outlined below may be required to achieve the scient ific goals of the study object ives and/or to 
ensure appropriate safety  monitoring of the study  subjects.
Some alterati ons f rom the current ly outlined dose and/or dosing regimen may be permitted based 
on newly  available data.
The fo llowing m ay occur:
Changes in the dose of the study drug administered may  occur.
The interval between doses may be lengthened if supported by  safet y, PD, and PK evidence. 
The PK/PD sampling scheme may  be modified during the study based on new ly available PK 
or PD data (eg, to obtain data closer to the tmax). If indicated, these collected samples may also  
be assayed in an exploratory  manner for m etabo lites and/or addit ional PD m arkers.
For PK blood draw, the timing of sampling collection may be changed wit hout changing the 
total number of samples which will be taken based on TAK -925- 1001 study  PK data.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 32of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Addit ional MWT, neuropsy chological tests (CCBT), and KSS evaluations could be added to 
characterize PK -PD rel ationships of TAK -925 based on TAK-925- 1001 study  resul ts.
Up to an addit ional 50 mL of blood may be drawn for PK and/or PD analyses. This blood 
volume may include repeat samples or modified PK/PDtime po ints based on emerging data. 
The total blood volume withdrawn fro m any single subject wi ll not exceed the maximum 
allowable vo lume during his/her participat ion in the ent ire study .
The timing of planned procedures for assessment of safet y procedures (eg, vital signs, ECG, 
safet y laboratory  tests) currently outlined in the protocol may  be modified during the trial 
based on newly available safet y, tolerabilit y, PK, or PD/bio marker data (eg, to obtain data 
closer to the time of peak plasma concentrations). These changes will not increase the number 
of study procedures for a given subject during h is/her participat ion in the entire study .
Addit ional laboratory  safet y tests m ay be added to blood samples previously  drawn to obtain 
additional safety  information (eg, adding creatine kinase to serum chemistry  panel that was 
already drawn). 
It is underst ood that the current study may emplo y some or none of the alterations described above. 
Any alterations described above made to this protocol to meet the study  objectives must be 
detailed by  the sponsor in a l etter to the Trial Master File and forwarded to the investigator for 
retenti on. The l etter willbe forwarded to the inst itutional review board (IRB)/independent ethics 
committee (IEC) at the discretion of the invest igator.
6.4 Study Beginning and End/Completion
6.4.1 Definition of Beginning of the Study
The overa ll study  begins when the first subject signs the study  informed consent form.
6.4.2 Definition of End of the Study
The overall study  ends when the l ast subject com pletes the l ast pl anned or follow -
up 
visit/interact ion associated with a planned visit (this can be a phone contact), discont inues fro m the 
study , or is l ost to foll ow-up (ie, the invest igator is unable to contact the subject).
6.4.3 Definition of Study Discontinuation
Study  discontinuation because of nonsafet y reasons, such as the fo llowing:
A finding (eg, P K, PD, efficacy, bio logic targets) from another nonclinical or clinical study  
using the study  treatm ent(s) resul ts in the study  being stopped for a nonsafet y-related reason.
Data from co mparator(s), drug(s) of the same class, or methodology(ies) used in th is study  
beco me available and results in the study  being stopped for a nonsafety- related reason.
The study  is stopped because of nonscient ific and nonsafet y reasons, such as slow enrollment.
Study  discontinuation because of safet y reasons:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 33of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Early study  term ination because of unanticipated concerns o f safety  to the study  subjects 
arising fro m clinical or nonclinical trials wit h the tri al treatm ent(s), com parator(s), drug(s) of 
the same class, or m ethodol ogy(ies) used in this study .
6.4.4 Criteria for Premature Term ination or Suspension of the Study
6.4.4.1 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of Good Clinical Practice (GCP), protocol, or contractual agreement, 
or is unable to ensure adequate performance of the study , or as otherwise permitted by  the 
contractual agreement.
6.4.4.2 Procedures for Premature Termination or Suspension of the Study or the Participation of 
the Study S ites
In the event that the sponsor, an IRB/IEC, or regulatory  authority elects to terminate or suspend the 
study  or the parti cipat ion of an invest igational site, a study -specific procedure for early 
termination or suspensio n will be provided by the sponsor ; the procedure will be fo llowed by  
applicable invest igational sites during the course of terminat ion or study  suspensi on.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 34of 91
Protocol Incorporating Amendment No. 01 08 May 2018
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.1 Inclusion Criteria
Subject eligibilit y is determined according to the following criteria before entry  into the study :
1.Understand the study  procedures and agree to participate by  providing wri tten informed 
consent.
2.Be willing and able to comply with all study  procedures and restrict ions.
3.Be a healt hy male, aged 18 to 40 y ears, inclusiv e, at the screening visit.
4.Have a body  mass index (BMI) ≥18.5 and ≤30.0 (kg/m2) at the screening visit.
5.Be a nonsmoker or have not used tobacco -or nicotine -containing products (eg, nicotine patch , 
chew, e -cigarettes, etc. ) for at l east 6 m onths before stu dy drug administration o f the init ial 
dose of study  drug.
6.Be judged to be in good health by the invest igator, based on clinical evaluat ions including 
laboratory  safety tests, m edical history , physical  examinat ion, 12- lead ECG, and vital sign 
measurements p erformed at the screening visit and before administration of the init ial dose of 
study  drug/invasive procedure.
7.Meet the fo llowing bi rth control  requi rements:
Is a m ale subject who i s sterile or agrees to use an appropriate method of contraception, 
includi ng a condom with or without spermicidal cream or jelly, fro m the first dose of study 
drug until <5 half -lives pl us 90 day s> after the last dose of study  drug. No restri ctions are 
requi red for a vasectomized male subject provided the subject is at least 1 year 
postbilateral vasectomy  procedure before the first dose of study  drug. A m ale subject 
whose vasectomy procedure was performed less than 1 y ear before the first dose of study  
drug m ust follow the same restrictions as a nonvasectomized man. Appropriate 
docum entati on of  surgical  procedure shoul d be provided.
Is a m ale subject who agrees to not donate sperm from study  drug administrati on on the 
first day  of the first dose until 5 half -lives plus 90 days after the last dose of study  drug 
administration.
8.Have regular sleep
-wake habits (eg, routinely  spending 6.5 to 8 hours sleeping night ly, not 
oversl eeping by  more than 3 hours, i e, total  sleep not more than 11 hours) as determined by 
investigator interviews and confirmed in 5 -day act igraphy records and who m regularly fall 
asleep between 9:30 PM and 12:00 AM.
9.Be willing to have act igraphy mo nitoring during the week before rando mizat ion and in each 
interval .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 35of 91
Protocol Incorporating Amendment No. 01 08 May 2018
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.Has parti cipated in another invest igational study  within 4 weeks (or based on local 
recommendat ions) before the pretrial (screening) visit. The 4 -week window will be derived 
from the date of the l ast study  procedure and/or AE related to the study  procedure in the 
previous study  to the screening visit of the current study . 
2.Is an emplo yee or immediate family member (eg, spouse, parent, child, sibling) of the clinical 
research unit or of the sponsor.
3.Has a history  of cancer (m alignancy).
4.Has a history  of significant m ultiple and/or severe allergies (eg, food, drug, latex allergy ) or 
has had an anaphylact ic reaction or significant intolerabilit y to prescript ion or nonprescript ion 
drugs or food.
5.Has a posit ive test result for hepatit is B surface a ntigen (HBsAg), hepat itis C virus (HCV), or 
HIV antibody /antigen, at Screening. Note: Subjects with positive hepat itis B virus (HBV) or 
HCV serology  may be enrolled if quant itative po lymerase chain react ion for HBV or HCV 
viral RNA is negat ive.
6.Has a posit ive alcoho l or drug screen at screening .
7.Had m ajor surgery , donated or l ost 1 uni t of blood (approximately 500 mL) wi thin 4 weeks 
before the pretrial (screening) visit. 
8.Is unable to refrain fro m or anti cipates the use of any  medicat ion, including prescrip tion and 
nonprescript ion drugs or herbal remedies beginning approximately 7 days before 
administration of the init ial dose of study  drug, throughout the study  (including washout 
intervals between treatment periods), until the poststudy  visit. Excluded food substances and 
medicat ions are listed in Appendix 4.
9.Has a history  of alcohol  consum ption exceeding 2 standard drinks per day on average (1 glass 
is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or dist illed 
spirits [29.5 m L/1 ounce] per day ).
10.Has excessive sleepiness defined by a self -reported Epworth Sleepiness Scale score at 
screening greater than 10; irregular work hours; or routine night -shift work within 1 mo nth 
before rando mizat ion. 
11.Current ly experiencing or having a history  of any known/suspected sl eep di sorder, any  
disorder associated with EDS, or any  diagnosis interfering wit h assessment of sleepiness.
12.Abnorm al findings on the init ial PSG conducted on Day -1 (check -in), as specified in the study 
manual.
13.Traveled ac ross 2 or more time zones 2 weeks or less before screening or any time during study 
participat ion. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 36of 91
Protocol Incorporating Amendment No. 01 08 May 2018
14.Current or previous history  of serious, severe, or unstable physical or psy chiatric illness that 
may affect sleep or wakefulness; current or past hi story  ofepilepsy or convulsio n; or any  
medical disorder that may  make the full complet ion of the study  unlikely .
15.Caffeine consumpt ion of more than 400 mg/day fo r 2 weeks before screening (1 serving of 
coffee is approximately equivalent to 120 mg of caffeine).
16. Par ticipants treated wi th medicat ions with CNS effects within 14 days o f check -in including 
sedat ing ant ihistamines, decongestant sympatho mimet ics, and/or monoamine oxidase 
inhibitors. Participants need to comply wit h convent ional phase 1 pharmaco logy study  
prohibited/excluded medications specified in protocol.
17.Hypertensio n or hi story  of hypertensio n. SBP ≥140 mmHg or DBP ≥90 mmHg is excluded.
18.Other significant cardiovascular risk factors including abnormal ECG QT interval findings and 
HR.
19.Screening ECG reveal s a QT interval wit h Frederica correction method (QTcF) 
>450 milliseconds.
7.3 Excluded Medications ,Supplements, Dietary Products
7.3.1 Concomitant Medications
The use of conco mitant m edicat ions (see Section
 9.1.3 ) 7 day s before administration of the first 
dose of study  drug, throughout the study (including the washout interval between tre atment 
periods), and unt il the f ollow-up visit is not permitted. Subjects must be instructed not to take any 
medicat ions wi thout first consul ting with the investigator. Any  concomi tant m edicat ion use must 
first be discussed wit h the sponsor, unless the investigator or designee considers immediate 
administration is nece ssitated.
The occasional use of acetaminophen (approximately <1 g/day) is allowed.
7.3.2 Fruit Juice
Subjects will refrain fro m consuming grapefruit juice, grapefruits, and products containing 
grapefruit beginning approximately 7 days before administration of th e first dose of study  drug, 
throughout the study (including the washout interval between tre atment periods), and until the 
follow-up visit.
Subjects also will refrain fro m consuming all juices 12 hours before and after administration of 
each dose of study  drug on PK sampling days (Days 1 and 2 of each treatment period) . 
Consumption o f all fruits other than grapefruit is allowed on all days of the study .
7.3.3 Alcohol
Alcoho l consumpt ion is not allowed during the entire study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 37of 91
Protocol Incorporating Amendment No. 01 08 May 2018
7.3.4 Caffeine
Subjects will refrain fro m consuming caffeinated beverages 24 hours before the screening visit and 
follow-up visit and fro m 24 hours before and until the last PK blood sample has been collected in 
each treatment period. At all other times, caffeinated beverages or xanthine -containing products 
will be limited to amounts of no more than 400mg/day.
7.3.5 Smoking
Smoking or use of nicotine or tobacco products is not allowed during the ent ire study .
7.4 Diet, Fluids, and Activity
7.4.1 Diet and Fluids
On Day  1,study  drug will be administered beginning at approximately  9:45PMfor tabl et 
(modafinil or placebo) and approximately  10:45PMfor IV infusio n (TAK -925 or pl acebo) for 
each treatment period. The modafinil or matching placebo will be given with 240 m L of water for 
PO administration. Subjects will be NPO for 2 hours after the PO modafinil/placebo 
administration.
Since study  drug administration does not begin until evening, subjects will have a standard 
breakfast, lunch, and dinner on Day 1. Snacks may be given up until approximately  8:30PMon the 
day of dosing (Day 1). No other food will be consumed unt il breakfast on Day 2. Subjects will fast 
from all food and drink except water between meals and snacks. The caloric content and 
composition of  meals will be the same for all subjects in each treatmen t peri od. On Day  2, 
breakfast will be provided after the fourthMWT, KSS, and cognitive testing have been completed. 
After the postdose procedures have been co mpleted, subsequent meals and snacks will be 
unrestri cted in caloric content, composit ion, and ti ming.
Subjects will refrain fro m consuming mustard greens (ie, kale, broccoli, watercress, collard 
greens, kohlrabi, Brussel sprouts, and mustard) and charbroiled meat 7 days before administratio n 
of the first dose of study  drug, throughout the study (including the washout interval between 
treatment periods), and unt il the fo llow
-up visit.
7.4.2 Activity
Subjects will avo id unaccustomed strenuous physical act ivity (ie, wei ght lift ing, run ning, 
bicycling, etc) fro m the screening visit unt il administration of the init ial dose of study  drug, 
throughout the study (including washout intervals between tre atment periods), and unt il the 
follow-up v isit.
Starti ng at approximately 8:30 PM , the subject’s activit ies will be restricted so that they  are not 
overstimulated or upset. Cell phone use will be restricted from approximately  8:30 PM until after 
recovery  sleep the next day. A ctivit ies permitted from approximately 8: 30PMon until the start of 
recovery  sleep areboard games, puzzles, adult coloring books, drawing, r eading, listening to 
music (not on cell phones) , watching televisio nor non -violent movies, and walking and tal king 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 38of 91
Protocol Incorporating Amendment No. 01 08 May 2018
with other participants/staff. Subjects may bring in small craft projects they are interested in or are 
working on.
7.5 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the following categories.
1.Pretreatment event (PTE) or AE. Th e subject has experienced a PTE or AE that requires early 
termination because cont inued participat ion imposes an unacceptable risk to the subject’s 
healt h or the subject is unwilling to continue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormali ties:
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 9.2.13.1 ), if the fo llowing ci rcumstances occur at any  
time during the study  drug treatm ent:
–Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8x upper limit 
of norm al (ULN), or
–ALT or AST >5x ULN and persists for more than 2 weeks, or
–ALT or AST >3x ULN in conjunction with elevated bilirubin >2x ULN or internationa l 
norm alized rati o (INR) >1.5 ULN, or
–ALT or AST >3x ULN with appearance of fat igue,  nausea, vomit ing, ri ght upper 
quadrant pai n or tenderness, fever, rash, and/or eosinophilia (>5%).
Suicidali ty:
–Study  drug should be discont inued immediately for subjects at imminent risk o f suicide 
per the C -SSRS (score of 5) or per the investigator’s clinical judgment.
BP increase:
–Sustained SBP >180 mmHg, sustained DBP >110 mmHg, or sustained increase in SBP 
>40 mmHg from baseline (measured just before the start of infusio n).
2.Significant protocol deviat ion. The discovery postrando mizat ion that the subject failed to meet  
protocol  entry  criteria or did not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health.
3.Lost to follow -up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to conta ct the subject must be documented in the subject’s source 
docum ents.
4.Voluntary  withdrawal. The subject wishes to withdraw from the study . The reason for 
withdrawal , if provided, should be recorded in the eCRF. Note: All attempts should be made to 
determine the underlying reason for the withdrawal and, where possible, the primary 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 39of 91
Protocol Incorporating Amendment No. 01 08 May 2018
underlying reason should be recorded (ie, withdrawal due to an AE should not be recorded in 
the “vo luntary withdrawal” category ).
5.Study  terminat ion. The sponsor, IRB, IEC, or regula tory agency  terminates the study .
6.Other. Note: The specific reasons should be recorded in the “specify” field o f the eCRF.
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section 7.5. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addit ion, efforts should be made to perform all procedures scheduled for the 
early  terminat ion visit.
If a BP reading meets 1of the criteria outlined in Section 7.5, the BP will be repeated at 5 minutes 
to confirm the va lue. If the subject has no cardiac or neurological symptoms, BP will cont inue to 
be observed at 15 -minute intervals. If there are cardiac or neurological symptoms, the drug should 
be discont inued immediately ,and the subject treated to lower BP according t o the best judgment of 
the invest igator and in accordance with good medical pract ice, and further emergency medical 
evaluat ion sought. El evation to >200 mmHg SBP or >120 mmHg DBP will result in immediate 
discontinuat ion of drug. Sustained BP elevation at v alues >180 mmHg and ≤200 mmHg SBP, 
>110 mmHg and ≤120 mmHg DBP, or a sustained increase of 40 mmHg SBP will result in the 
infusio n being discont inued, with duration o f increased BP tolerated being 1 hour or based on 
investigator judgment and in accordance with good medical  pract ice. If the BP does not fall after 
drug di scontinuati on wi thin 30 to 60 minutes, the subject should be treated according to the best 
judgment of the investigator and in accordance wit h good m edical pract ice. If the drug is 
discontin ued in any  one subject due to a BP increase, the subject will not be rechallenged with 
TAK -925 infusio n.
7.7 Subject Replacement
If a subject discont inues from the study , a repl acement subject may  be enrolled, if deemed 
appropriate by  the investi gator and spon sor. The study  site shoul d contact the sponsor for the 
replacement of subject’s treatment assignment and allocat ion number.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 40of 91
Protocol Incorporating Amendment No. 01 08 May 2018
8.0 CLINICAL STUDY MATERIAL MANAGEMENT
8.1 Clinical Study Drug 
Details regarding the composit ion and extemporaneous preparation of the active drug and placebo 
are found in the Pharmacy Manual. Clinical study drug will be packaged to support enrollment and 
replacement subjects as required. When a replacement subject is required, the sponsor needs to be 
contacted before dosing.
8.1.1 Clinical StudyDrug Labeling
Clinical study  drug will  be affixed wit h a clinical label in accordance with regulatory 
requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
Clinical study drug must be stored in a secure, limit ed-access locat ion under the storage condi tions 
specified on the label. Inventory  (recei pt and di spensing) of study  drug m ust be recorded by  an 
authori zed unblinded person at the trial site.
8.1.3 Clinical Study Drug Blinding
This is a double -blind study; the investigator and subjects are blinded to tre atment assignment. 
Study  drug will be provided to an unblinded pharmacist or other qualified study site personnel who  
will blind the study  supplies. Treatm ent identity (nam e and strength or potency ) will be incl uded 
on the study  drug container label; rando mizat ion code/disclosure envelopes or lists will be 
provi ded.
8.1.4 Randomization Code Creation and Storage
Randomization personnel o f the sponsor or designee will generate the randomization schedule. All 
rando mizat ion informat ion will  be stored in a secured are a, accessible only by authorized 
personnel.
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure
The clinical study drug blind will be maintained through a randomizat ion schedule held by the site 
unblinded pharmacist. The clinical study  drug blind shall n ot be broken by  the invest igator unless 
inform ation concerning the clinical study  drug is necessary  for the m edical  treatm ent of the 
subject. If possible, the medical mo nitor shoul d be contacted before the study drug blind is broken. 
Unblinding will be per formed per the standard operating procedures of the site contract research 
organi zation.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 41of 91
Protocol Incorporating Amendment No. 01 08 May 2018
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
The invest igator is responsible for keeping accurate records of the clinical study drug received 
from the spon sor or desi gnee, the am ount dispensed to and returned by  the subjects, and the 
amount remaining at the end of the study. For all study sites, the local country sponsor personnel or 
designee will provide appropriate documentation that must be completed for clinical study drug 
accountabilit y, return, and destruction.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 42of 91
Protocol Incorporating Amendment No. 01 08 May 2018
9.0 STUDY PROCEDURES
The fo llowing sect ions describe the study  procedures to be performed and data to be collected as 
indicated in the Schedule o f Study Procedures (Section 3.0). For each procedure, subjects are to be 
assessed by  the same investi gator or si te personnel whenever possible. Please note that it may  
beco me necessary  to perform  the f ollowing procedures at unscheduled t ime periods, per the 
discreti on of  the invest igator.
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
Inform ed consent m ust be obtained before the subject enters the study  and before any 
protocol -directed procedures are performed. The requirements of informed consent are described 
in Appendix B.
9.1.1.1 Assignment of Screening and Randomization Nu mbers
All consented subjects will be given a unique screening number that will be used to identify the 
subject for all procedures that occur before randomizat ion or allocat ion. Each subject will be 
assigned only  1 screening number. Screening numbers must n ot be reused for different subjects. 
Any subject who is screened mult iple times will be assigned a new screening number for each 
screening event.
All eligible subjects will be rando mly allocated and will receive a rando mizat ion number. The 
rando mizat ion number i dentifies the subject for all procedures occurring after randomizat ion. 
Once a rando mization number is assigned to a subject, it can never be reassigned to another 
subject. A single subject cannot be assigned more than 1 rando mizat ion number.
9.1.1.2 Study D rug Assignment
On Day  1 of Treatment Peri od 1, subj ects will be assigned a randomizat ion number in ascending 
numerical order at the clinical site. The rando mizat ion number encodes the sequence in which each 
subject will receive TAK -925 LD m g, TAK -925 HD mg , modafinil , or pl acebo, according to the 
rando mizat ion schedule generated before the study. Each subject will be dispensed blinded study 
drug, l abeled wi th his/her unique randomizat ion number, throughout the study .
9.1.2 Inclusion and Exclusion 
Each subject wi ll be assessed through randomization, according to the eligibilit y criteria provi ded 
in Section
 7.0.
9.1.3 Medical History, Demographics, and Prior and Conc omitant Medications
Qualified site personnel will collect subject significant medical history  (past and concurrent 
medical condit ions), per the site’s standard of care and appropriate clinical judgment, and also 
subject demographics.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 43of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Qualified site personn el will review subject pri or and conco mitant m edicat ion use. Medicat ions 
are defined as prescription and over -the-counter drugs, vaccines, supplements, nutraceuticals, and 
PO herbal preparations.
9.2 Clinical Procedures and Assessments
9.2.1 Full Physical Examinatio n
Qualified site personnel will conduct full physical examinat ions.
9.2.2 Height and Weight
Body  weight and height will be obtained with the subject’s shoes off, and jacket or coat removed.
9.2.3 BMI
BMI equals a subject’s weight in kilograms divided by height in mete rs squared (BMI=kg/m2). 
BMI will be rounded to the nearest whole number according to the standard convent ion of 0.1 to 
0.4, round down, and 0.5 to 0.9, round up.
9.2.4 Vital Signs
Body  temperature will be measured with an oral (temperature taken at floor of the mouth) or 
tympanic thermo meter. The same method (ie, oral or tympanic) must be used for all subsequent 
measurements for each individual subject and should be the same for all subjects.
Subjects should rest in a bed with the head o f the bed at 30 degrees fo r at least 5 minutes before 
vital signs are m easured. Vi tal signs will include HR, respiratory  rate, SBP, and DBP. The same 
method (eg, same size cuff, manual or automated) must be used for all measurements for each 
individual subject and should be the sam e for all subjects. 
Subjects should cont inue to rest in a bed with the head of the bed at 30 degrees fro m the time of 
dosing unt il 4hours postdose except to stand for the measurement of standing vital signs (if 
needed) or other trial -related procedure.
9.2.5 Continuous Monitoring with Digital Technology
BP data will be collected using a wrist -or finger -based device for measurement of radial arterial 
pressure or digital arterial pressure. BP and HR will be continuously mo nitored during the 
confinement period. BP data will be co llected during the NPSG on the first night of the study and 
continuously during study  drug infusi on such that time points of BP collect ion during these 
periods are approximately matched.
9.2.6 12-Lead ECG
Speci al care must be taken for proper l ead placement by  qualified personnel. Skin should be clean 
and dry  before lead placement. Subjects may need to be shaved to ensure proper lead placement.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 44of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Subjects should be resting in a semirecumbent position for at least 5 minutes before each ECG 
measurem ent.
QTcF intervals will be calculated in this study .
For each treatment period, a predose ECG will be obtained wit hin approximately 1 hour before 
study  drug dosing. This measurement will be used as the baseline assessment. The principal 
investigator shoul d arrange to have a study  cardi ologist available as needed to review ECG 
tracings wit h abnormalit ies.
During each treatment period, if a subject demonstrates an increase in QTcF interval 
≥40milliseconds compared wit h a predose baseline measurement, the EC G will be repeated 
within 5 minutes. The average value of the QTcF interval fro m the 2 ECGs will represent the value 
at that time point. If the average QTcF interval increase from baseline for any postdose time point 
is ≥40 milliseconds, the subject will c ontinue to be monitored by  repeat 12 -lead ECGs every 60 
minutes for at least 4 hours or until the QTcF interval is within 40 milliseconds of the baseline 
value. If prolongat ion of the QTcF interval ≥40milliseconds persists, a consultation wit h a study  
cardiologist may  be appropri ate and the sponsor should be notified.
If the QTcF interval is ≥500 milliseconds, the sponsor should be notified and the ECGs should be 
reviewed by a cardio logist. The subject should be mo nitored by  telemetry  (unt il the QTcF inter val 
is <500 milliseconds) or should be considered for transfer to a location where closer monitoring is 
available.
If the subject has unstable hemodynamics, or has any clinically significant dysrhyt hmias noted by 
telemetry , the subject should be immediatel y transferred to an acute care setting for definit ive 
therapy .
If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in place or 
mark the posit ion of the electrodes for subsequent ECGs. To mark the position o f the electrodes, 
12-lead electrode sites will be marked on the skin of each subject with an ECG skin marker pen to 
ensure reproducible electrode placement.
The fo llowing ECG param eters will be recorded: HR, PR interval, QRS interval, QT interval, 
QTcF interval, and the interpretation of the ECG profile by  the princi pal investi gator.
9.2.7 Study Drug Administration
On Day  1 of each treatm ent peri od, tri al drug (TAK -925 LD m g, TAK -925 HD m g, modafinil 
[300 mg], or placebo) will be administered as described in Sect ion
 7.4.1 .
9.2.8 C-SSRS
Suicidal  ideati on will  be assessed using the C -SSRS at the times stipulated in the Schedule of 
Study  Procedures (see Section 3.0). Two versio ns of the C -SSRS will be used in this study : the 
Screening/Baseline C -SSRS Lifet ime and the Since -Last-Visit C-SSRS. Any suicidal ideat ion or 
suicidal behavi or during tri al periods detected by  C-SSRS will be recorded as AEs. The 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 45of 91
Protocol Incorporating Amendment No. 01 08 May 2018
investigator will ensure that any  suicidal  ideation or behavior is medically addressed, including 
assessment and treatment by  qualified m edical  personnel .
9.2.9 Drug -Liking VAS
Following recovery  sleep in each treatment period, subjects will undergo a self -administered 
100-point (0 = strongly dislike to 100 =strongly like) drug -liking VAS to assess abuse potential.
9.2.10 Actigraphy
Subjects will be mo nitored wi th actigraphy from  Day  
-6 through Day  -1 of each treatm ent peri od 
to confirm that subjects have a normal sleep -wake cy cle (defined as at l east 6 hours of sleep per 
night, and other criteria as specified in the inclusio n/exclusion criteria). The actigraphy will be 
deployed on Day  -6 and used cont inuously unt il subjects arrive at the study site. Act igraphy data 
will not be collected while subjects are confined.
9.2.11 Sleep Deprivation
Subjects will be required to stay  awake in between MWT tests. During the MW study , subjects 
will be instructe d to sit quiet ly and remain awake for as long as possible during each of the 
40-minute MWT sessio ns. Each MWT test will be terminated after 40 minutes of wakefulness or 
after the onset of an EEG -
detected sleep signal lasting up to 30- second epoch of any sl eep stage.
9.2.12 AE Monitoring
AE monitoring begins after signing of the informed consent form. Changes in subject health status 
from the baseline assessment until study  drug administration should be captured in the subject’s 
medical history . A com plete descri ption of AE collections and procedures is provided in 
Secti on10.0.
9.2.13 Laboratory Procedures and Assessments
Laboratory  samples will be collected in accordance with acce ptable laboratory  procedures. 
Samples will  be taken on the day s stipulated in the Schedule of Study Procedures (Section 3.0).
9.2.13.1 Clinical Laboratory T ests
Hematology
Hem atology will consist of the following tests:
Erythrocy tes (RBCs) Leukocytes (WBCs) with absolute differential
Hematocrit Platelets
Hemoglobin
Abbreviations: RBCs, red blood cells; WBCs, white blood cells.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 46of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Chemistry 
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel:
Albumin Chloride
Alkaline phosphatase Creatinine
ALT GGT
AST Glucose
Bilirubin (total), if above ULN total bilirubin will be 
fractionatedPotassium
Blood urea nitrogen Protein (total)
Calcium Sodium
Carbon dioxide
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; ULN, 
upper limit of normal.
If subjects experience ALT or AST >3× ULN, follow -up laboratory tests (at a minimum, serum  
alkaline phosphatase, ALT, AST, total bilirubin, γ -glutamyl  transferase, and INR) should be 
perform ed within a maximum o f 7 days and preferably wit hin 48 to 72 hours after the abnormalit y 
was noted.
If ALT or AST remains elevated >3× ULN on these 2 c onsecutive occasio ns, the invest igator must 
contact the medical mo nitor for consi derat ion of addi tional testing, cl ose m onitoring, possible 
discontinuat ion of study  drug, and di scussio n of the relevant subject details and possible 
alternat ive etio logies. T he abnormalit y shoul d be recorded as an AE.
Please refer to Section 7.5for subject discont inuat ion criteria regarding abnormal LFTs and 
Secti on 10.2.8.4 for guidance on reporting abnormal LFTs.
Urinalysis
Urinalysis will consist of the fo llowing tests:
Blood Nitrite
Glucose Protein
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of red blood 
cells/high -power field, white blood cells/high -power field, and casts.
9.2.13.2 Diagnostic Screening
Serum
The serum diagnostic screening assessment will include the fo llowing tests:
HIV Hepa titis screen ( HBsAg , HCV)
Abbreviations: HBsAg, hepatitis B surface antigen ; HCV, hepatitis C virus; HIV, human immunodeficiency virus .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 47of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Alcohol Screen
Subjects will undergo an alcoho l breath test. A urine alcoho l test m ay be perform ed at the 
discreti on of the invest igator.
Urine Drug Screen
The urine drug screening assessment will include the fo llowing tests:
Amphetamines MDMA
Barbiturates Methadone/metabolite
Benzodiazepines Opiates
Bupreno rphine/metabolite Oxycodone/oxy morphone
Cannabinoids Phency clidine
Cocaine/metabolites
Abbreviation: MDMA, 3,4 -methy lenedioxy -methamphetamine.
9.3 PK, Biomarker, PD, and Pharmacogenomic Samples
9.3.1 PK, Biomarker, PD, and Pharmacogenomic Evaluations
Samples for PK, bio marker, PD, and pharmacogenomic (PGx) analysis will be co llected as 
specified in the Schedule of Study Procedures (Sectio n 3.0).Please refer to the Laboratory Manua l 
for inform ation on the collection, processing, and shipment of samples to the central laboratory.
The decisio n as to which plasma samples collected will be assayed for evaluation o f PK will be 
determined by the sponso r. If indicated, these samples may also be assayed and/or pooled to 
measure m etabo lites in an exploratory  manner.
It is ant icipated that the total blood volume drawn in this study  will be approximately  285 mL.
Primary specimen co llection parameters are pro vided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Blood sample for PGx Blood DNA Blood sample for PGx analysis Optional
Plasma sample for PK Blood Plasma Plasma sample for PK Mandatory
Abbreviations: PGx, pharmacogenomic; PK, pharmacokinetics.
9.3.2 PK Measurements 
The PK parameters of TAK -925 and its metabo lites M -I and M -II will be determined from plasma 
concentrations from all evaluable subjects using noncompart mental analysis methods. Actual 
sampling t imes, rather than scheduled sampling t imes, will be used in all co mputations invo lving 
sampling t imes.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 48of 91
Protocol Incorporating Amendment No. 01 08 May 2018
The fo llowing PK parameters will be calculated from plasma concentrations of TAK -925 and i ts 
metabo lites M -I and M -II, as data permit:
Cmax AUC last
Ceoi AUC ∞
Tmax CL (TAK -925 only)
t1/2z Vss
Vz (TAK -925 only )
Addit ional PK parameters may  be calculated as appropriate. A detailed PK analysis plan will be 
prepared before PK parameter computation.
The PK profile of modafinil has already  been reported and will not be evaluated in this study .
9.3.2.1 Plasma for PK Measurements
Blood sam ples (one 3 -mL sample per scheduled t ime) for PK analysis o f TAK -925 will be 
collected into chilled blood collect ion tubes (vacutainer) containing the ant icoagulant dipotassi um 
ethylenediaminetetraacetic a cid (K2EDTA )according to the schedules in Sect ion 3.0.
The actual time of sample collect ion will be recorded on the source document and eCRF. Sampl ing 
time points may be adjusted based on the preliminary emerging concentration data collected fro m 
prior subj ect(s), but the total number of samples collected per subject should not exceed the 
planned number.
Instructi ons for collect ing, processing, and s hipping of PK samples are provided in the Laboratory 
Manual.
9.3.2.2 PK Sample Analysis
Plasma concentrations o f TAK -925 and its metabolites MI and MII will be measured by a 
validated high -performance liquid chro matography with tandem mass spectrometry  assay. Part of 
the archival plasma samples may be used for potential analysis o f unknown metabo lite 
characterizat ion, if appropri ate. 
9.3.3 Biomarker Measurements
EEG will be used as the primary translat ional bio marker to assess the efficacy of TAK -925. There 
is the potential to add other biomarkers which are reported to be increased by sleep disturbances, 
including serum superoxi de dismutase, pl asma Aβ42, low -densit y lipoprotein receptor
-related 
protein, and so luble receptors for advanced glycat ion end products [30,31] . However , as the study 
is being conducted in healt hy norm al subjects who are undergoing only 1 night of sleep 
deprivat ion in each period , the likelihood of finding significant changes, as well as changes related 
to study  drug, i s low. Therefore, fluid bio markers will not be collected in this study . 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 49of 91
Protocol Incorporating Amendment No. 01 08 May 2018
9.3.4 PDMeasurements
The PD assessments described below will be performed according to the Sched ule of Study  
Procedures in Sect ion 3.0. Addi tional details regarding these PD assessments are provided in the 
Study  Manual.
9.3.4.1 PSG
Subjects will undergo an 8 -hour (11:00 PM -7:00 AM) NPSG to exclude any sleep disorders. The 
PSG will be evaluated shortly after complet ion utilizing the American Academy of Sleep Criteria 
Scoring to ensure that subjects do not have an abnormal PSG before rando mizat ion into the study  
(scoring criteria specified in study  manual ). The Day  -1 PSG will be performed once; subsequent 
treatm ent peri ods will  not requi re the NPSG before dosing and testing.
When the final MWT test and cognit ive testing has been completed, subjects will b e allowed to 
sleep (recovery  sleep) for at approximately 6 hours. PSG recording will be done during this time.
9.3.4.2 MWT
The MWT is a validated object ive measure that evaluates a person’s abilit y to remain awake under 
soporific condit ions for a defined period of time. As there is no bio logical measure of wakefulness, 
this is measured indirect ly by the inabilit y or delayed tendency to fall asleep. This tendency to fall 
asleep is measured via EEG
-derived sleep latency in MWT.
9.3.4.3 KSS
The KSS is a 9- item Likert -type rat ing scale for assessing subjective sleepiness. 1 =very alert, 
3
=alert, 5 = neither alert nor sleepy, 7 = sleepy (but not fight ing sleep), 9 = very sleepy (fighting 
sleep). This scale measures the subject ive level o f sleepiness at a particular time durin g the day. On 
this scale subjects indicate which level best reflects the psy cho-physical sate experienced in the 
last 10 minutes.
9.3.4.4 CCBT
The CCBT is a com puter -based cognit ive assessment sy stem  consist ing of a battery of several 
neuropsy chological tests relevant to the effects of sleep deprivation . The cognit ion areas covered 
by the battery  include reacti on time, processing speed, attention and sustained vigilance, and 
episodic memory .The test battery  will take approximately  20minutes.
9.3.4.5 POMS
The POMS i s a we ll-validated self -report m easure of m ood s tates. The original English versio n 
consists of 65 items, consist ing of adjectives which are rates with regard to the participant’s 
current m ood on a 6 -point Likert scale ranging from 0 (not at all) to 5 (extremely ). Answers 
provi de standardized scores for 6 ident ified subscales: anger -hostilit y, confusi on-bewilderm ent, 
depressio n-deject ion, fatigue -inertia, tension -anxiety , and vi gor-activit y. Higher scores indicate 
more negative m ood states, except for vigor -activit y for which l ower scores denote a m ore 
negat ive mood state.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 50of 91
Protocol Incorporating Amendment No. 01 08 May 2018
9.3.5 PGx Measurements 
9.3.5.1 Blood Sample for DNA PGx Measurements
Sampling of who le blood for PGx analysis is optional in this study and will only be performed for 
subjects who provide consent to particip ate in this assessment.
PGx is the study  of variati ons of  DNA characteristics as related to drug response. There is 
increasing evidence that an individual’s genet ic background may impact the PK (absorption, 
distribut ion, metabo lism, and excretion), PD (pha rmaco logic effects), and/or clinical effects 
(efficacy  and/or safet y) of a drug.
PGx research in this study  may be conducted to understand how individual genet ic variat ion in 
subjects impacts their response to study  drug treatment. This information may  also be used, for 
example, to develop a better understanding o f the safet y and efficacy o f TAK-925 and other study 
drugs, to increase understanding of the disease/condit ion being studied and other related 
condi tions, to gain a better understanding o f the drug pharmacology, and to generate information 
needed for research, development, and regulatory  approval  of tests to predi ct response to 
TAK -925.
One 5 -mL who le blood sample for DNA iso lation will be co llected at Day -1from each consented 
subject in the study . If necessary  and f easible, a second aliquot of blood may  be taken at a l ater 
time point if iso lation of DNA from the first sample was not successful or possible.
Since, PGx is an evo lving science, many genes and their funct ions are not y et fully understo od. 
Future data may  suggest a rol e of these genes in drug response, which may lead to addit ional 
hypothesis -generating exploratory  research and diagnostic development on stored samples.
Detailed instructions for the handling and shipping of samples are pro vided in the Laboratory  
Manual.
9.3.5.2 Biological Sample Retention and Destruction
In this study, blood samples for PGx analysis will be collected as described in Section 9.3.5.1 . The 
genet ic materi al will be ini tially stored at a vendor or comparable laboratory , under contract to 
Takeda, with validated procedures in place, and then preserved and retained at a long -termstorage 
vendor, or a comparable laboratory , with validated procedures in place, for up to but not longer 
than 15 y ears f rom the end of the study  when the study  report is signed, or if less, the maximum 
period permitted under applicable law or until consen t is wi thdrawn.
The sponsor and vendors working wit h the sponsor will have access to the samples collected and 
any test results. All samples co llected during the study will be stored securely wit h limited access, 
and the sponsor will require anyo ne who wor ks with the samples to agree to hold the research 
inform ation and any results in confidence.
The sample will be labeled with a unique sample ident ifier as in the main study  but using a code 
that is different from the code attached to the healt h informat ion and other clinical test results 
collected in the study . The sample and data are linked to personal healt h informat ion with code 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 51of 91
Protocol Incorporating Amendment No. 01 08 May 2018
numbers; the samples are stripped of all personal ident ifying informat ion but a key  linking the 
samples to clinical analysis da ta exists. This link means that the subject may be ident ified but only 
indirect ly. The sample ident ifier will be kept secure by or on behalf o f the sponsor.
Subjects who consented and provided a PGx sample for DNA analysis can wit hdraw their consent 
at any time and request disposal o f a stored sample. Any remaining sample that can be ident ified as 
coming fro m the subject will be destroy ed. The investigator and sponsor may cont inue to use and 
distribute any  information and test results gathered before the re quest to withdraw.
9.3.6 Confinement
Subjects will report to the clinical site on Day  -1 in each treatment period and will leave after 
completion of all study -related procedures on Day  2.
At the discretion o f the investigator, subjects may be requested to remain in the clinical site lo nger.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 52of 91
Protocol Incorporating Amendment No. 01 08 May 2018
10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study; it does not necessarily  have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is con sidered rel ated to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate t herapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptom s:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be rec orded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion,evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only shoul d be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  procedure. However, if the subject experiences a worsening or complicat ion 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 53of 91
Protocol Incorporating Amendment No. 01 08 May 2018
of such a concurrent medical history  condi tion, the worsening or complication sho uld be 
recorded appropriately as an AE (worsening or complicat ion occurs after informed consent is 
signed). Invest igators should ensure that the event term recorded captures the change in the 
condi tion (eg, “worsening of…”).
If a subject has a pre -exist ingepisodi c condi tion (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an AE if the episodes beco me more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from baseline in the condit ion (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which wou ld be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
shoul d be recorded as a new AE. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Changes in severit y ofAEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeri es or therapi es) that were scheduled before the signing o f 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the cond ition shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigat ional 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in co nsultation wit h the sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the eCRF, to capture this important safet y inform ation consistently in the database. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 54of 91
Protocol Incorporating Amendment No. 01 08 May 2018
AEs associ ated wi th an overdose will be docum ented on AE case report forms (CRFs) 
according to Section 10.0.
SAEs of overdose should be reported according to the procedure outlined in Sect ion 10.2.8 .
In the event of drug overdose, the subject should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOS PITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to preve nt items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
AEs that fulfill  1 or m ore of the seri ous cri teria above are to be considered SAEs and s hould be 
reported and fo llowed up in the same manner (see Sections 10.1 and 10.1.1 )
.
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories o f severit y/intensity are:
Mild: An AE that is usually transient and may require only minimal treatment or 
therapeuti c intervent ion. The event does not generally  interfere wi th usual 
activit ies o f daily living.
Moderate: An AE that is usually alleviated with addit ional specific therapeutic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: An AE that interrupts usual activit ies of daily living, or significant ly affects 
clinical status, or may  require intensive therapeutic intervent ion.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 55of 91
Protocol Incorporating Amendment No. 01 08 May 2018
10.2.2 Assigning Causality o f AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including the course after withdrawal o f the drug), or for which a causal 
relationship is at least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out , although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsibl e.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the subject and/or 
investigator.
10.2.4 End Date 
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.5 Pattern of AE (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  medicat ion.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  medicat ion was st opped for a reason other than the particular AE 
eg,the study  has been terminated, the subject died, dosing with study  medicat ion had not y et 
started or dosing wit h study  medicat ion was already  stopped before the onset of the AE.
Dose reduced –the dose wa s reduced due to the particular AE.
Dose increased –the dose was increased due to the particular AE.
Drug interrupted –the dose was interrupted due to the particular AE.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 56of 91
Protocol Incorporating Amendment No. 01 08 May 2018
10.2.7 Outcome
Recovered/reso lved –subject returned to first assessment status with respec t to the AE.
Recovering/resolving –the intensit y is lowered by  1 or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the su bject died fro m a cause other 
than the particular AE with the condit ion rem aining “recovering/resolving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  valu e on the l ast day  of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining “Not recovered/not 
resolved.”
Recovered/ Reso lved wit h sequelae –the subject recovered from an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal  –an AE that is considered as the cause of death.
Unknown –the cours e of the AE cannot be fo llowed up due to hospi tal change or residence 
change at the end of the subject’s participation in the study .
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.8.1 Collection Period
Collect ion of AEs (ie, AEs , SAEs, and Abnorm al LFTs) will co mmence at the time the subject 
signs the inform ed consent. Routi ne collect ion of AEs will cont inue unt il approximately 30 days 
after the l ast dose of invest igational product. For subjects who discont inue before the 
adminis tration of  study  medicati on, AEs will  be followed until the subject discont inues study 
participat ion. 
10.2.8.2 Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing an 
SAE before the first exposure to investigational product must be monitored until the symptoms 
subside and any clini cally  relevant changes in laboratory  values have returned to baseline or there 
is a satisfactory explanat ion for the change. Nonserious AEs that begin before the first exposure to 
investigat ional product, related or unrelated to the study  procedure, need n ot be fo llowed-up for 
the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to baseline or until there is a sat isfactory  explanat ion for the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 57of 91
Protocol Incorporating Amendment No. 01 08 May 2018
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/Intensi ty.
Causalit y (Invest igator’s opinio n of the causal relationship between the event and 
administration of study  drug[s ]).
Action taken with study  drug.
Outcom e of event.
Seriousness.
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in English and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zedas serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Appendix 14.1.1 .
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occurring on treatment.
SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator sh ould com plete a follow -up SAE form  or provi de other wri tten docum entati on and 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 58of 91
Protocol Incorporating Amendment No. 01 08 May 2018
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be s ent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.8.4 Reporting of Abnormal LFTs
If a subject i s noted to have ALT or AST elevated >3 ×ULN on 2 consecut ive occasions, the 
abnorm ality shoul d be recorded as an AE. In addition, an LFT Increases eCRF must be co mpleted 
provi ding addit ional information on relevant recent history , risk factors, clinical si gns and 
symptoms and results of any addit ional diagnosti c tests performed.
If a subject is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and re ported 
as per Secti on 10.2.8.3 . The i nvest igator must contact the medical mo nitor for discussio n of the 
relevant subject details and possible altern ative etiol ogies, such as acute viral hepat itis A or B or 
other acute liver disease. Follow -up laboratory  tests as described in Section 9.2.13.1 must also be 
perfor med. In addit ion, an LFT Increases eCRF must be completed and transmitted with the 
Takeda SAE form (as per Section 10.2.9 )
. 
10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
and any  other applicable SAEs to regulatory  authori ties, invest igators and IRBs or IECs, as 
applicable, in accordance with national regulat ions in the countries where the study  is conducted. 
Relative to the first awareness o f the event by /or further provisio n to the sponsor or sponsor’s 
designee, suspected unexpected serious adverse reactions will be submitted within 7 d ays for fatal 
and life -threatening events and 15 days for other seri ous events, unless otherwise required by  
national regulat ions. The sponsor will also prepare an expedited report for other safet y issues 
where these might materially  alter the current bene fit-risk assessment of an investigational 
medicinal product or that would be sufficient to consider changes in the invest igational medicinal 
products administration or in the overall conduct of the study . The invest igational site also will  
forward a copy  of all expedited reports to his or her IRB or IEC in accordance wit h nat ional 
regul ations.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 59of 91
Protocol Incorporating Amendment No. 01 08 May 2018
11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized before database lock. This document will 
provi de further details regarding the definit ion of analysis variables and analysis methodology  to 
address all study  object ives.
A blinded data review will be conducted before database lock. This review will assess the accuracy 
and co mpleteness of the study  database, s ubject evaluabilit y, and appropri ateness of the planned 
statist ical methods.
11.1.1 Analysis Sets
11.1.1.1 Safety Set
The safet y set will consist of all subjects who were enrolled and received at least 1 dose of study  
drug. Subjects in this analysis set will be used for d emographic, baseline characteristics, and safet y 
summaries.
11.1.1.2 PK Set
The PK analysis set will consist of all subjects who received at least 1 dose of study drug and have 
at least 1 m easurable pl asma concentrati on.
11.1.1.3 PD Set
The PD analysis set will consist of a ll subjects who received at least 1 dose of study drug and have 
at least 1 evaluable PD endpo int.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Dem ographic and other baseline characterist ics will be summarized and listed by treatment 
sequence a nd overall. Descriptive statist ics will be used to summarize data for continuous 
variables such as age and weight (number of subjects [N] , mean, median, SD, minimum, and 
maximum) and for categorical variables such as sex, ethnicit y, and race (number and percentage of 
subjects wi thin each category ). Medi cal history  and medicat ion history  will be listed by subject.
11.1.3 PK Analysis
Plasma concentrations of TAK- 925 and i ts metaboli tes M -I and M -II and PK parameter estimates 
will be listed for each subject and sum marized using descript ive statist ics by each time point for 
each dose.
Addit ionally , the relat ionships between TAK -925 plasma concentrations and selected measures of 
efficacy  (eg, MWT, CCBT, and KSS) and safet y (eg, BP) will be explored as deemed appropria te.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 60of 91
Protocol Incorporating Amendment No. 01 08 May 2018
11.1.4 PD Analysis 
11.1.4.1 Primary and Secondary Analyses
Sleep l atency  on the MWT will be summarized (N, mean, median, SD, minimum, and maximum) 
by treatment and time.
The effect of TAK -925 will be evaluated with a mixed effects model appropriate for a 4- period 
crossover study . The response variable in the model will be the observed value of sleep latency . 
The model will contain fixed effects for sequence, period, treatm ent (TAK -925 LD, TAK -925 HD, 
modafinil, and pl acebo), time (as a categorical variable), and th e treatm ent-by-time interacti on, 
and a rando m effect for subject.
The estimated mean sleep latency for each treatment and the associated standard error and 95% CI
will be extracted from the model at each time, along with all treatment differences and assoc iated 
standard errors, 95% CIs, and p -values. The same quant ities, averaged over all t imepo ints at which 
an MWT is performed, will also be extracted from the model using an appropriate contrast. The 
study  object ives will be addressed using the results of t he average treatment dif ference across all 
time points.
A similar analysis will be performed for the KSS.
11.1.4.2 Exploratory Analyses
11.1.5 Safety Analysis
Unless stated otherwise, b aseline for safety  parameters i s defined as the last measurement 
collected before study  drug administrati on,and summary  stati stics will be N, mean, median, SD, 
minimum, and maximum.
11.1.5.1 AEs
All AEs will be coded by  system  organ cl ass and preferred term using MedDRA (Medical 
Dictionary for Regulatory  Activities). TEAEs will be summarized by treatment.
11.1.5.2 Clinical Laboratory Evaluations
Clinical laboratory test data will b e summarized for baseline, postdose, and changes fro m baseline 
by treatment and time. Only the scheduled measurements will be included in the summary.
11.1.5.3 Vital Signs
HRand BPdata will be s ummarized for b aseline (defined as Day  -1 of each treatment peri od), 
postdose , and change fro m time- matched b aseline by  treatm ent and time. Only the scheduled 
measurements w ill be included in the summary.
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 61of 91
Protocol Incorporating Amendment No. 01 08 May 2018
The change from t ime-matched baseline will be analyzed using a statist ical model of the same 
form as for the primary end point . The estimated mean change from time- matched baseline for each 
treatm ent and the associated standard error and 95% CI will be extracted from the model at each 
time, al ong wi th all treatm ent differences and associated standard errors, 95% CIs, and p -values. 
The same quant ities, averaged over all postdose timepo ints, will also be extracted from the model
using an appropriate contrast.
All other vita l signs will be summarized for b aseline (pre -dose on Day 1 o f each period), postdose, 
and change fro m baseline by  treatm ent and time.
11.1.5.4 ECGs
ECG data will be summarized for b aseline, postdose, and changes fro m baseline by  treatm ent and 
time. Only  the scheduled m easurements will be included in the summary . No stati stical tests will 
be perform ed.
11.1.5.5 C
-SSRS
C-SSRS data will be listed.
11.1.5.6 Drug -liking VAS
Drug -liking VAS data will be listed.
11.1.5.7 POMS
POMS data will be summarized for b aseline, postdose, and changes fro m baseline by  treatm ent 
and time.
11.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
11.3 Determination of Sample Size
The sample size just ificat ion is based on a similar study to assess the alertness -prom oting effects of 
MK-0249, a hi stamine subt ype-3 receptor inverse agonist, and modafinil 200 mg, in healt hy 
sleep -deprived males [
1]. In that study , investi gators observed a mean increase in sleep latency in 
the MWT of  with modafinil 200 mg compared with placebo at 6 hours postdose and 
a within-subject standard deviat ion of approximately  . With simila r vari ability, 
16
completers will provide approximately power for detecting a difference in sleep latency in the 
MWT between TAK -925 and pl acebo if the true increase over placebo is . This result is 
based on a 2 -sided test wi th a .
To account for dropouts, approximately 20 subjects will be enrolled. If a subject discontinues fro m 
the study , a repl acement subject may  be enrolled, if deemed appropriate by the invest igator and 
sponsor. The study  site shoul d contact the sponso r for the replacement of subject’s treatment 
assignment and allocat ion number.
CCI
CCI
CCI
CCI
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 62of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Sixteen co mpleters will also provide adequate precisio n for the est imation of changes in BP. 
Assuming a standard deviat ion for the difference between periods in the change fro m baseline SBP 
of [20], a 95% CI for the true mean change in SBP between 1dose level of TAK -925 
and placebo will extend no m ore than  from the observed difference. For example, if 
the observed difference between TAK -925 and pl acebo i s , then the CI for the true 
difference will extend from , and this is considered to represent adequate
preci sion for the est imated treatment difference.
CCI
CCI
CCI
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 63of 91
Protocol Incorporating Amendment No. 01 08 May 2018
12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. So urce documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and study site guarantee access to source documents by the sponsor or its 
designee (cont ract research organization) and by the IRB or IEC.
All aspects of the study  and i ts docum entati on will be subject to review by the sponsor or the 
sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
investigator’s b inder, study  drug, subj ect m edical records, informed consent documentation, and 
review of eCRFs and associated source documents. It is important that the invest igator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the Food and Drug Administration [FDA], the United Kingdo m 
Medicines and Healthcare Products Regulatory Agency, the Pharmaceut icals and Medical Devices 
Agency o f Japan). If the study site is contacted for an inspect ion by a re gulatory  body , the sponsor 
shoul d be notified immediately. The invest igator guarantees access for qualit y assurance auditors 
to all study  docum ents as described in Section 12.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 64of 91
Protocol Incorporating Amendment No. 01 08 May 2018
13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the International Conference on Harmo nisat ion (ICH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the study  according to applicable local or 
regional regulatory  requi rements and ali gn his or her conduct in accordance wit h the 
“Responsibilit ies of the Investigator” that are listed in Appendix A. The principles of Helsinki are 
addressed through the protocol and through appendices containing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regi on. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abs tinence fro m 
voting must also be obtained. Those American sites unwilling to provide names and tit les of all 
members because of privacy and conflict of interest concerns should instead provide a Federal 
Wide Assurance Number or comparable number assigned b y the Department of Health and 
Hum an Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the investigator’s brochure, a copy of 
the informed con sent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will ship drug/notify site once the sponsor has 
confirmed the adequacy of s ite regulatory  docum entati on and, when applicable, the sponsor has 
received permissio n from competent authori ty to begin the study . Until the si te receives 
drug/notificat ion no protocol activit ies, including screening, may occur.
Sites m ust adhere to all r equirements sti pulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requi rements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB or IEC, and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for the se items m ust be provi ded to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 65of 91
Protocol Incorporating Amendment No. 01 08 May 2018
13.2 Subject Information, Informed Consent, and Subject Authori zation
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The inform ed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefits, and the date 
inform ed consent i s given. The informed consent form will detail the requirements of t he 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and, if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor before use.
Theinformed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the det ailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appr opriate by the IRB or IEC. If the subject is not capable o f rendering adequate 
written inform ed consent, then the subject’s legally  acceptable representative may  provide such 
consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally  acceptable represen tative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent an d before the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date th e informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and before subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signe d, the ori ginal  informed consent form , subject authori zation form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 66of 91
Protocol Incorporating Amendment No. 01 08 May 2018
All revised informed consent forms must be revi ewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subj ect shoul d receive a copy  of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA and RNA analysis can withdraw 
their consent and request disposal o f a stored sample at any time before analysis. Notify sponsor of 
consent wi thdrawal.
13.3 Subject Confidentiality
The sponsor and designees affirm and uphol d the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o fthe subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authorit y(eg, the FDA, the Medicines and Healthcare products Regulatory Agency, the 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical r ecords requires the specific 
authori zation of the subject as part of the informed consent process (see Section
 13.2).
Copi es of  any subject source doc uments that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
13.4 Publication, Disclosure, and Clinical Trial Registration Pol icy
13.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  results, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consen t of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 67of 91
Protocol Incorporating Amendment No. 01 08 May 2018
this secti on and th e Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Trial Registration 
To ensure that information on clinical trials reaches the public in a timely manner and to comply 
with applicable l aws, regul ations and guidance, Takeda will, at a minimum, register all 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible webs ites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registri es, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call the site 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llmen t, they shoul d be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site.
13.4.3 Clinical Trial Results Disclosure 
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury  to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 68of 91
Protocol Incorporating Amendment No. 01 08 May 2018
14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contact Information 
Study  contact numbers can be found in the Study  Manual, the communicat ion plan, or other 
similar documents provided to the site.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 69of 91
Protocol Incorporating Amendment No. 01 08 May 2018
14.1.2 INVESTIGATOR AGREEMENT 
I confi rm that I have read and that I understand this protocol, the invest igator’s brochure, package 
insert and any  other product information provided by  the sponsor. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to p rotect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2.9 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix A).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 70of 91
Protocol Incorporating Amendment No. 01 08 May 2018
14.1.3 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Study -Related Responsibilit ies template. The vendors i dentified for specific study -related 
activit ies will perform these act ivities in full or in partnership wi th the sponsor.
14.1.4 List of A bbreviations
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC ∞ area under the first moment plasma concentration -time curve from time 0 to infinity
AUC last area under the plasma concentration -time curve from time 0 to time of the last 
quantifiable concentration
BMI body mass index
BP blood pressure
Ca2+calcium
CCBT Camb ridge Cognitio nComputerized Battery of Tests
Ceoi plasma concentration observed at the end of infusion
CFR Code of Federal Regulations
CL total clearance after intravenous administration
Cmax maximum observed plasma concentration
CNS central nervous system 
CRF case report form
CSF cerebrospinal fluid
C-SSRS Columbia –Suicide Severity Rating Scale
DBP diastolic blood pressure
ECG electrocardiogram
eCRF electronic case report form
EDS excessive daytime somnolence
EEG electroencephalogram
FDA Food and Drug Administration
FIH first-in-human
FSH follicle -stimulating hormone
GCP Good Clinical Practice
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HD high dose
HED human equivalent dose
HIV human immunodeficiency virus
HR heart rate
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 71of 91
Protocol Incorporating Amendment No. 01 08 May 2018
ICH International Conference on Harmonisation
ICSD -3 International Classification of Sleep Disorders, 3rdedition
IEC independent ethics committee
INR internatio nal no rmalized ratio
IRB institutional review board
IV intravenous
KSS Karolinska Sleepiness Scale
LD low dose
LFT liver function test
M-I, M-II metabolites of TAK -925
MedDRA Medical Dictionary for Regulatory Activities
MOA mechanism of action
MWT maintenance of wakefulness test
NPSG nocturnal polysomnography
NT1 narcolepsy type 1
NT2 narcolepsy type 2
OX orexin
OX1R orexin receptor 1
OXR2 orexin receptor 2
PD pharmacodynamic(s)
PGx pharmacogenomic(s)
PK pharmacokinetic(s)
PO oral administration or orally
POMS Profile of Mood States
PSG polysomnography  
PTE pretreatment event
QTcF QT interval with Frederica correction method
REM rapid eye movement
SAE serious adverse event
SBP systolic blood pressure
t1/2z terminal disposition phase half -life
TEAE treatment -emergent adverse event
tmax time of first occurrence of C max
ULN upper limit of normal
VAS visual analog scale
Vss volume of distribution at steady state after intravenous administration
Vz volume of distribution during the terminal disposition phase after intravenous 
administration
WT wild ty pe
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 72of 91
Protocol Incorporating Amendment No. 01 08 May 2018
15.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be docum ented in the Data Management Plan. 
AEs, m edical history , and concurrent conditions will be coded using MedDRA. Drugs will be 
coded using the World Healt h Organizat ion Drug Di ctionary.
15.1 CRFs (Electronic and Paper)
Com pleted eCRFs are required for each s ubject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify ite ms, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informa tion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the eCRFs for completeness a nd accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of the clinical study database, any chan ge of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator with use of change and modificat ion records of 
the eCRFs. The principal investigator must review the data change for completeness and accuracy, 
and must sign an d date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensu re accuracy  of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wr itten permissio n of the sponsor.
15.2 Record Retention
The invest igator agrees to keep the records stipulated in Section
 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, sub ject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs including the audit trails, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regu latory  authori ties, the sponsor or its designees. Any  source 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 73of 91
Protocol Incorporating Amendment No. 01 08 May 2018
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 Section 4.9.5 requires the investigator to retain essent ial docum ents specified in ICH E6 
(Secti on 8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is no t approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorities are notified. In addit ion, ICH E6 
Secti on 4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulator y requi rements or for a time specified in the Clinical Study  Site Agreement 
between the invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the institutio n shoul d contact and receive written approval fro m the 
sponsor before disposing of any  such documents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 74of 91
Protocol Incorporating Amendment No. 01 08 May 2018
16.0 REFERENCES
1. Iannone R, Palcza J, Renger JJ, Calder N, Cerchio K, Gottesdiener K, et al. Acute 
alertness -prom oting effects of a novel histamine subt ype-3 receptor inverse agonist in 
healt hy sleep -deprived m ale vol unteers. Clin Pharmacol Ther 2010;88(6):831 -9.
2. Ohno Y, Matsumoto K, Hirose A, Nakamura M. Effects of perospirone hydrochloride, a 
novel ant ipsychotic agent, on EEG in rabbits and spinal reflex in cats. Clinical Report 
1997;31(2):879 -92.
3. Scammell TE, Winrow CJ. Orexin receptors: pharmaco logy and therapeuti c opportuni ties. 
Annu Rev Pharmacol Toxicol 2011;51:243 -66.
4. Ruoff C, Rye D. The ICSD -3 and DSM -5 gui delines for di agno sing narco lepsy: clinical 
relevance and practicalit y. Curr Med Res Opin 2016:1 -12.
5. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH. Hy pocretin (orexin) l evels in 
cerebrospinal fluid of pat ients with narco lepsy: relati onship to catapl exy and HLA 
DQB 1*0602 status. Sleep 2002;25(7):733-6.
6. De la Herran -Arita AK, Garcia -Garcia F. Narco lepsy as an immune -mediated disease. Sleep 
Disord 2014;2014:792687.
7. Schneider L, Mignot E. Diagnosis and Management of Narco lepsy. Semin Neurol 
2017;37(4):446 -60.
8. Singh AK, Mahlios J, Mignot E. Genet ic associat ion, seasonal infect ions and autoimmune 
basis of narco lepsy. J Autoimmun 2013;43:26 -31.
9. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. 
Reduced number of hypocretin neurons i n human narco lepsy. Neuron 2000;27(3):469-74.
10. Lopez R, Barateau L, Evangelista E, Chenini S, Robert P, Jaussent I, et al. Temporal changes 
in the cerebrospinal fluid level o f hypocretin -1 and histamine in narcolepsy. Sleep 2016.
11. Tabuchi S, Tsunemat su T, Bl ack SW, Tominaga M, Maruy ama M, Takagi  K, et al . 
Condi tional ablat ion of orexin/hypocretin neurons: a new mouse model for the study of 
narco lepsy and orexin system funct ion. J Neurosci 2014;34(19):6495-509.
12. Kawai M, O'Hara R, Einen M, Lin L, Mignot E. Narcol epsy in African Americans. Sleep 
2015;38(11):1673 -81.
13. Black J, Swick T, Bogan R, Lai C, Carter LP. Impact of sodium oxybate, modafinil, and 
combinat ion treatment on excessive dayt ime sleepiness in patients who have narco lepsy with 
or wi thout catapl exy. Sleep Med 2016;24:57-62.
14. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy  and i ts treatm ent wi th 
stimulants. ASDA standards of practice. Sleep 1994;17(4):352 -71.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 75of 91
Protocol Incorporating Amendment No. 01 08 May 2018
15. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Ly ons DM, Migno t E. Ci rcadian and 
homeostatic regulat ion of hypocretin in a primate model: implicat ions for the consolidat ion 
of wakefulness. J Neurosci 2003;23(8):3555 -60.
16. Salomon RM, Kennedy JS, Johnson BW, Urbano Blackford J, Schmidt DE, Kwentus J, et al. 
Treatmen t enhances ultradian rhyt hms o f CSF m onoamine metabolites in pat ients with 
major depressive episodes. Neuropsy chopharm acology 2005;30(11):2082 -91.
17. Huang SC, Dai YW, Lee YH, Chiou LC, Hwang LL. Orexins depo larize rostral ventrolateral 
medulla neurons an d increase arteri al pressure and heart rate in rats mainly via orexin 2 
receptors. J Pharmaco l Exp Ther 2010;334(2):522-9.
18. Gasior M, Freeman J, Zammit G, Donnelly P, Gao J, Ferreira -Cornwell  MC, et al . 
Maintenance of wakefulness with lisdexamfetamine d imesylate, compared wit h placebo and 
armodafinil in healt hy adult m ales undergo ing acute sleep loss. J Clin Psychopharmaco l 
2014;34(6):690 -6.
19. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant 
versus placebo or mod afinil in pat ients with narcolepsy: a double -blind, rando mised trial. 
Lancet Neurol 2013;12(11):1068-75.
20. Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of 
single doses of armodafinil in healt hy subjects during a nocturn al period of  acute sl eep l oss. 
Curr Med Res Opin 2006;22(1):159
-67.
21. Broughton RJ, Fleming JA, George CF, Hill JD, Kry ger MH, Mol dofsky H, et al . 
Randomized, double -blind, pl acebo -controlled crossover trial o f modafinil in the treatment 
of excessive day time sleepiness in narco lepsy. Neurol ogy 1997;49(2):444 -51.
22. Kaida K, Takahashi M, Akerstedt T, Nakata A, Otsuka Y, Haratani T, et al. Validation o f the 
Karo linska sleepiness scale against performance and EEG variables. Clin Neurophysio l 
2006;117(7):157 4-81.
23. Reyner LA, Horne JA. Falling asleep whilst driving: are drivers aware of prior sleepiness? 
Int J Legal Med 1998;111(3):120 -
3.
24. Veddeng A, Husby  T, Engelsen IB, Kent A, Flaatten H. Impact of night shift s on 
laparoscopic skills and cognit ive fun ction among gyneco logists. Acta Obstet Gyneco l Scand 
2014;93(12):1255 -61.
25. Estrada A, Kelley  AM, Webb CM, Athy  JR, Crowley JS. Modafinil as a replacement for 
dextroam phetamine for sustaining alertness in military  helicopter pilots. Aviat Space 
Environ M ed 2012;83(6):556 -64.
26. Husby  T, Torgersen J, Fl aatten H. Cogni tive effects of hospital calls in anaesthesio logists. 
Acta Anaesthesio l Scand 2014;58(2):177 -84.
27. James LM, Iannone R, Palcza J, Renger JJ, Calder N, Cerchio K, et al. Effect of a novel 
histamine subt ype-3 receptor inverse agonist and modafinil on EEG power spectra during 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 76of 91
Protocol Incorporating Amendment No. 01 08 May 2018
sleep deprivat ion and recovery  sleep in male vol unteers. Psy chopharmaco logy (Berl ) 
2011;215(4):643 -53.
28. Xu TR, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: mult i-functional therapeut ic 
targets for sleeping disorders, eating disorders, drug addict ion, cancers and other 
physio logical disorders. Cell Signal 2013;25(12):2413-23.
29. Jara CO, Popp R, Zulley  J, Haj ak G, Gei sler P. Determinants of depressive symptoms in 
narcoleptic pat ients with and wi thout catapl exy. J Nerv Ment Dis 2011;199(5):329-34.
30. Wei M, Zhao B, Huo K, Deng Y, Shang S, Liu J, et al. Sleep Deprivat ion Induced Plasma 
Amylo id-beta Transport Disturbance in Healt hy Young Adults. J Alzheimers Dis 
2017;57( 3):899 -906.
31. An H, Cho MH, Kim DH, Chung S, Yoon SY. Orexin Impairs the Phagocy tosis and 
Degradation of Amylo id-beta Fibrils by  Microglial Cells. J Alzheimers Dis 
2017;58(1):253 -61.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 77of 91
Protocol Incorporating Amendment No. 01 08 May 2018
17.0 APPENDICES
Appendix AResponsibiliti es of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” ( Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study  related procedures, i ncluding study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in t he conduct of the study  are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 Code of Federal Regulations (CFR ) Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH, and local 
regul ations, are m et.
9.Obtain valid informed consent from each subject who participate s in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses a nd disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a sep arate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maint ain these data for a minimum o f 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 78of 91
Protocol Incorporating Amendment No. 01 08 May 2018
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approv al from the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 79of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Appendix BElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the c onduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable risks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the ex tent to whi ch confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subje ct or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study .
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or the subject’s 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 80of 91
Protocol Incorporating Amendment No. 01 08 May 2018
legally acceptable representative may discont inue participat ion at any  time wi thout penal ty or 
lossof benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally ac ceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of PGx analysis will not be disclo sed to an indi vidual, unless 
prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion m ust contain the following 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies an d other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protec tion as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 81of 91
Protocol Incorporating Amendment No. 01 08 May 2018
25.Male subjects must use highly effect ive contraceptio n(as defined in the informed consent) 
from signing the informed consent throughout the duration of the study  and f or 5 half -lives 
PLUS 90 day s after the last dose of study drug. If the partner or wife of the subject is found to 
be pregnant during the study , the invest igator will offer the subject the cho ice to receive 
unblinded treatment informat ion. 
26.A statement that clinical trial informat ion from this study  will be publicly disclosed in a 
publicly  accessible website, such as ClinicalTrials.gov.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 82of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Appendix CInvestigator Consent to the Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, US, and Japan), including the fo llowing:
Takeda, its affiliates, and licensing partners.
Business partners assist ing T akeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and ph armacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websit es.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 83of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Appendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Subjects and Their Female Partn ers
From  signing of informed consent, throughout the duration of the study, and for 5 half -lives PLUS 
90 days after last dose of study drug, nonsterilized** male subjects who are sexually act ive wit h a 
female partner of childbearing potential* must use bar rier contraception (eg, condom wit h or 
without spermicidal cream or jelly ). In addi tion, they  must be advised not to donate sperm during 
this period. Females of childbearing potential who are partners of male subjects are also advised to 
use addit ional con tracepti on as shown in the list containing highly effect ive/effect ive 
contraception below.
In studies with no risk of fetotoxicit y/teratogenicit y/genotoxi city: Male subjects are not required to 
use barrier contraception.
Definitions and Procedures for Cont raception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* A wom an is considered a woman of childbearing potential, ie, fert ile, fo llowing menarche and 
until becoming post -menopausal unless per manently sterile. Perm anent sterilizat ion methods 
include hysterectomy, and bilateral oophorectomy . A postmenopausal state is defined as no 
menses for 12 months wit hout an alternative medical cause. A high fo llicle -stimulat ing hormone 
(FSH) level in the po stmenopausal range (FSH >40 IU/L) may be used to confirm a 
post-menopausal state in y ounger wom en (eg, those <45 years old) or women who are not using 
horm onal contracepti on or horm onal replacement therapy. However, in the absence of 12 months 
of amenorrhe a, a single FSH measurement is insufficient.
** Sterilized males should be at least 1 year postbilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
The follow ing procedures apply for contraception and pregnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly an d 
correctly ). In this study, where medicat ions and devices containing hormones are included, the 
only acceptable methods of contraception are: 
Non-Hormonal Methods: 
–Intrauterine device.
–Bilateral tubal occlusio n.
–Vasectomized partner (provi ded that partner is the sole sexual partner of the study  
participant and that the vasectomized partner has received medical assessment of the 
surgi cal success.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 84of 91
Protocol Incorporating Amendment No. 01 08 May 2018
–True sexual abst inence, only if this is in line wit h the preferred and usual life style o f the 
subject. True abst inence is defined as refraining from heterosexual intercourse during 
the ent ire peri od of  the study , from 1 month before the first dose until 5 half -lives 
PLUS 30 days after last dose.
Horm onal Methods: Horm onal contracepti onmay be suscept ible to interaction with the 
investigat ive co mpound, comparator, concomitant medicat ions, which may reduce the 
efficacy  of the contracepti on method (Eval uate on com pound-by- compound and 
protocol -
by-protocol  basis and obtain clinical pharmaco logy justification).
–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least 3 months before the first dose of study  drug 
OR combined with a barrier method (male condom, female condo m or diaphra gm) if 
for shorter durati on unt il she has been on contraceptive for 3 months;
Oral †.
Intravaginal † (eg, ring).
transderm al †.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation1 
initiated at least 3 months before the first do se of study  drug OR combined with a 
barrier method (male condo m, female condo m or diaphragm) if shorter till she has bee n 
on contraceptive for 3 months;
Oral †.
Injectable.
Implantable.
2.If genotoxicit y/teratogenicit y/embry otoxi city is unlikely  to be caused by the investigat ional 
drug, com parator, background therapy  or standard of care medicationseffect ive methods of 
contraception (there may  be a hi gher than 1% failure rate) are: 
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m).
Progestogen only hormonal contraception, where inhibit ion of ovulat ion is not the primary 
mode of act ion PLUS condom wit h or without spermicide.
3.Unacceptable methods of contraception are:
Periodic abst inence (eg, cal endar, ovul ation, symptothermal, post -ovulation methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 85of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.
4.Subjects will be provided with information on highly effect ive/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they  understand the requirement s for avo idance of pregnancy and 
sperm  donat ion during the study .
5.During the study, all subjects will receive cont inued gui dance wit h respect to the avo idance of 
pregnancy and sperm donat ion as part of the study procedures. Such guidance should include a 
reminder of the fo llowing:
a)contraceptive requirements of the study
b)reasons for use of barrier methods (ie, condom) in males with pregnant partners
c)assessment of subject compliance through questions such as
i.Have you used the contraception consistent ly and co rrectly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
Pregnancy
Women of childbearing potential will not be included in this study .
Any pregnancies in the female partner of a male subject during the study or for 5 hal f-lives PLUS 
90 day safter the l ast dose, shoul d also be recorded fo llowing authori zation from the subject’s 
partner. 
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to rec eive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by the invest igator. 
Pregnancies in female partners of subjects rando mized to placebo need not be fo llowed. 
If the female partner of a m ale subject agrees to the primary  care physician being informed, the 
investigator should notify  the primary care physician that the female partner of the subject was 
participat ing in a clinical study at the time she became pregnant and provid e details o f the study  
drug the m ale subject received (blinded or unblinded, as applicable).
All pregnancies in female partners of male subjects who were on active study  drug (including 
comparator, if applicable) will be followed up to final outcome, using the pregnancy form. 
Pregnancies will remain blinded to the study  team . The outcom e, including any premature 
termination, must be reported to the sponsor. An evaluat ion after the birth o f the child will also be 
conducted.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 86of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Appendix EDetailed Description of Amendments to Text
The primary sect ionsof the protocol affected by the changes in Amendment 01 are indicated . The 
corresponding text has been revised throughout the protocol.
Change 1:Removed Sustained Attention to R esponse Task (SART )assessment throughout 
protocol  and updated study  schemat ic accordingly.
The primary  change occurs in Section 3.0SCHEDULE OF STUDY PROCEDURES
Descript ion 
of change:Removed SART under pharmacodynamic evaluat ions.
Rationale for Change: Change in rat ing vendor who required change in rat ing scales.
The fo llowing sect ions also contain this change:
Secti on 1.0STUDY SUMMARY
Secti on 2.0STUDY SCHEMATIC
Secti on 5.1.3 Exploratory  Objectives
Secti on 5.2.4 Exploratory  Endpo ints
Secti on 6.1Study Design
Secti on 6.2.3.2 Secondary Endpo ints
Secti on 6.2.4 Critical Procedures Based on Study Object ives: Timing o f Procedures
Secti on 6.3Study Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters
Secti on 9.3.4 PDMeasurements
Secti on 11.1.1.3 PD Set
Section 11.1.4.2 Exploratory  Analyses
Secti on 14.1.4 List of A bbreviat ions
Secti on 16.0 REFERENCES
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 87of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Change 2:Replaced Cogstate Cognitive Computerized Battery of Tests with Cambridge 
Cogni tion Com puterized Battery  of Tests (CCBT) .
The primary  change occurs in Section 5.1.3 Exploratory  Objectives
Initial 
wording:
Amended 
or new 
wording:
Rationale for Change: Change in rat ing vendor who required change in rat ing scales.
The fo llowing sect ions also contain this change:
Secti on 1.0STUDY SUMMARY
Secti on 2.0STUDY SCHEMATIC
Secti on 3.0SCHEDULE OF STUDY PROCEDURES
Secti on 5.1.3 Exploratory  Objectives
Secti on 6.2.3.2 Secondary Endpo ints
Secti on 9.3.4.4 CCBT
Secti on 14.1.4 List of A bbreviat ions
CCI
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 88of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Change 3:Updated alcoho l consumption restrictions.
The primary  change occurs in Section 7.3.3 Alcohol
Rationale for Change: Align protocol text with exclusion criteria.
Initial 
wording:Subjects will refrain fro m consuming alcoho l 7 days before the screening visit and 
follow-up visit and fro m 7 days before and unt il the last PK blood sample has been 
collected in each treatment period. At all other times, alcoho l consumpt ion is limit ed 
to no m ore than approximately 3 alcoholic beverages or equivalent (1 alcoho lic 
beverage is approximately equivalent to: beer [354 mL/12 oz], wine [118 mL/4 oz], or 
distilled spirits [29.5 mL/1 oz]) per day.
Amended 
or new 
wording:Subjects will refrain f rom consuming alcohol  7 days before the screening visit and 
follow-up visit and fro m 7 days before and unt il the last PK blood sample has been 
collected in each treatment period. At all other times, a Alcohol consumpt ion is not 
allowed during the e ntire study limited to no more than approximately 3 alcoho lic 
beverages or equivalent (1 alcoholic beverage is approximately  equivalent to: beer 
[354 mL/12 oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz]) per day .
Change 4:Updated caffeine consumpt ion restrictions.
The primary  change occurs in Section 7.3.4 Caffeine
Rationale for Change: Align protocol text with exclusion criteria.
Initial 
wording:Subjects will refrain fro m consuming caffeinated beverages 24 hours before the 
screening visit and fo llow-up visit and from 24 hours before and unt il the last PK 
blood sam ple has been collected in each treatment period. At all other times, 
caffeinated beverages or xanthine -containing products will be limited to amounts of 
no m ore than 6 uni ts per day  (1unit=120 mg of caffeine) .
Amended 
or new 
wording:Subjects will refrain fro m consuming caffeinated beverages 24 hours before the 
screening visit and fo llow-up visit and from 24 hours before and unt il the last PK 
blood sam ple has been collected in each treatment period. At all other times, 
caffeinated beverages or xanthine -containing products will be limited to amounts of 
no m ore than 6 uni ts per day  (1unit=120 mg of caffeine) 400mg/day .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 89of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Change 5:Updated smoking restrict ions.
The primary  change occurs in Section 7.3.5 Smoking
Rationale for Change: Align protocol text with inclusion criteria.
Initial 
wording:Tobacco or nicotine -containing products are restricted for 1 hour before the PSG and 
40 minutes before the MWT. No excessive consumpt ion per day  is allowed (>10 
cigarettes/day ) during the study .
Amended 
or new 
wording:Tobacco Smoking or use of nicotine- containing or tobacco products are restricted for 
1 hour before the PSG and 40 minutes before the MWT. No excessive consumpt ion 
per day  is allowed (>10 ci garettes/day )is not allowed during the entire study .
Change 6:Added dose levels selected for the low dose (LD) and high dose (HD).
The primary  change occurs in Section. 6.2.2 Rationale for Dose .
Initial 
wording:This study will evaluate 2 dose levels of TAK -925, LD and HD. The dose level of HD 
will be determined once study  TAK -925- 1001 has completed the dose escalations in 
the healt hy norm al cohorts. The m aximum  dose of the healt hy cohorts in 
TAK -
925-1001 was originally 134.4 mg and an amendment is being planne d to 
increase the maximum dose to 420 mg. The HD may be equivalent to the highest dose 
level ( plasma concentrati on expected to be approximately 883 ng/mL, which is the 
estimated observed plasma concentration at steady state when 420 mg is administered) 
where safet y and tol erabili ty of 9-hour IV infusio n of TAK -925 is confirmed in the 
TAK -925- 1001 s tudy. The aim of the LDis to evaluate a dose that will result in effects 
on wakefulness (as assessed by the MWT) that are greater than those seen on placebo, 
buta dose that is pharmacologically different than the HD in concentration. The LD 
will also be considered above or equal to the dose level that is expected to achieve a 
target concentration associated with effects on wakefulness, which is equivalent to the 
human equivalent dose (HED) calculated based on WT monkey pharmaco logy studies 
as described below.  
 
 
 
 
 
 
 
 
This difference will be taken into consideration when choosing 
the LD in sleep -deprived healt hy subjects.
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 90of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Amended 
or new 
wording:This Based on the currently available information, this study will evaluate 2 dose 
levels o f TAK -925, LD and HD. The a low dose level of HD will be determined once 
study  TAK -925-1001 has com pleted the dose escalations in the healt hy norm al 
cohorts. The maximum 44 mg (LD) and high dose o f the healt hy cohorts in 
 
112 mg.  
.The HD 
of 112 mg is administered) where was selected based on the safety and tolerability 
of results in adult subjects from the ongoing FIH TAK -925-1001 study. Doses up 
to and including 134.4 mg, the maximum dose tested so far in healthy volunteers, 
were safe and well tolerated with no severe AEs or SAEs. All subjects dosed with 
112 mg TAK -925 had acceptable safety and tolerability during the 9-hour IV 
infusio n of TAK -925 is co nfirmed in the TAK -925- 1001 study . The aim  of the . The 
44 mg LD iswas selected to evaluate a dose that willmay resul t in effects on 
wakefulness (as assessed by the MWT) that are greater than those seen on of placebo, 
but a dose that is  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This difference will be Thus, the potential difference in the 
pharmacological response to TAK -925 has also been taken into consideration when 
choosing the LD and HD in sleep -deprived h ealthy subjects.
CCI
CCI
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -925
Study ID TAK -925-1002 Page 91of 91
Protocol Incorporating Amendment No. 01 08 May 2018
Rationale for Change : Doses selected based on currently available safet y and tol erabili ty resul ts 
in healthy adult subjects in the ongoing TAK -925- 1001 study .
The fo llowing sect ions also contain this change:
Secti on 1.0STUDY SUMMARY
Secti on 5.1.2 Secondary Object ives
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
   
  
   
  
   
  
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d680867dfeAmendment 1 to A Phase 1b, 4-Period Crossover, Placebo-Controlled, Randomized, Single Dose Study to
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in Sleep-Deprived
Healthy Adults Utilizing Modafinil as an Active Comparator
Clinical Pharmacology Approval 08-May-2018 20:54 UTC
Biostatistics Approval 09-May-2018 15:18 UTC
Clinical Science Approval 09-May-2018 19:40 UTC
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
